
<html lang="en"     class="pb-page"  data-request-id="4fe868e4-6187-4e02-86a5-66e2c48130cc"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2018.61.issue-5;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.7b01605;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening" /></meta><meta name="dc.Creator" content="Samuel&#xA;H.  Myers" /></meta><meta name="dc.Creator" content="Carolin  Temps" /></meta><meta name="dc.Creator" content="Douglas R.  Houston" /></meta><meta name="dc.Creator" content="Valerie G.  Brunton" /></meta><meta name="dc.Creator" content="Asier  Unciti-Broceta" /></meta><meta name="dc.Description" content="Pyrazolopyrimidines with potent antiproliferative properties were developed by an adaptive strategy that applies ligand-based design and phenotypic screening iteratively and is informed by biochemi..." /></meta><meta name="Description" content="Pyrazolopyrimidines with potent antiproliferative properties were developed by an adaptive strategy that applies ligand-based design and phenotypic screening iteratively and is informed by biochemi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 21, 2018" /></meta><meta name="dc.Type" content="rapid-communication" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01605" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01605" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01605" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01605" /></link>
        
    
    

<title>Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01605" /></meta><meta property="og:title" content="Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0011.jpeg" /></meta><meta property="og:description" content="Pyrazolopyrimidines with potent antiproliferative properties were developed by an adaptive strategy that applies ligand-based design and phenotypic screening iteratively and is informed by biochemical assays. To drive development toward specific oncopathways, compounds were tested against cancer cells that overexpress, or not, AXL kinase. Identified phenotypic hits were found to inhibit oncotargets AXL, RET, and FLT3. Subsequent optimization generated antiproliferative lead compounds with unique selectivity profiles, including selective AXL inhibitors and a highly potent inhibitor of FLT3." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01605"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01605">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01605&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01605&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01605&amp;href=/doi/10.1021/acs.jmedchem.7b01605" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2104-2110</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00047" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Brief Article</span><a href="/doi/10.1021/acs.jmedchem.7b01824" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Samuel H. Myers</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samuel H. Myers</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samuel%0AH.++Myers">Samuel H. Myers</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carolin Temps</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carolin Temps</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carolin++Temps">Carolin Temps</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Douglas R. Houston</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Douglas R. Houston</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Institute of Quantitative Biology, Biochemistry and Biotechnology, University of Edinburgh, Edinburgh EH9 3BF, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Douglas+R.++Houston">Douglas R. Houston</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Valerie G. Brunton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Valerie G. Brunton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Valerie+G.++Brunton">Valerie G. Brunton</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Asier Unciti-Broceta</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Asier Unciti-Broceta</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: (44)1317773584. Fax: (44)1317773520. E-mail: <a href="/cdn-cgi/l/email-protection#3d7c4e54584f1368535e544954107f4f525e58495c7d545a5050135859135c5e134856"><span class="__cf_email__" data-cfemail="3372405a56411d665d505a475a1e71415c50564752735a545e5e1d56571d52501d4658">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Asier++Unciti-Broceta">Asier Unciti-Broceta</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1029-2855" title="Orcid link">http://orcid.org/0000-0003-1029-2855</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01605&amp;href=/doi/10.1021%2Facs.jmedchem.7b01605" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2104–2110</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 21, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 October 2017</li><li><span class="item_label"><b>Published</b> online</span>21 February 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 March 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01605" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01605</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by text">with CC-BY<a href="/page/policy/authorchoice_ccby_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01605"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3365</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">13</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01605" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Samuel\nH.&quot;,&quot;last_name&quot;:&quot;Myers&quot;},{&quot;first_name&quot;:&quot;Carolin&quot;,&quot;last_name&quot;:&quot;Temps&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;R. Houston&quot;},{&quot;first_name&quot;:&quot;Valerie&quot;,&quot;last_name&quot;:&quot;G. Brunton&quot;},{&quot;first_name&quot;:&quot;Asier&quot;,&quot;last_name&quot;:&quot;Unciti-Broceta&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;2104-2110&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01605&quot;},&quot;abstract&quot;:&quot;Pyrazolopyrimidines with potent antiproliferative properties were developed by an adaptive strategy that applies ligand-based design and phenotypic screening iteratively and is informed by biochemical assays. To drive development toward specific oncopathways, compounds were tested against cancer cells that overexpress, or not, AXL kinase. Identified phenotypic hits were found to inhibit oncotargets AXL, RET, and FLT3. Subsequent optimization generated antiproliferative lead compounds with unique selectivity profiles, including selective AXL inhibitors and a highly potent inhibitor of FLT3.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01605&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01605" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01605&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01605" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01605&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01605" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01605&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01605&amp;href=/doi/10.1021/acs.jmedchem.7b01605" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01605" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01605" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01605%26sid%3Dliteratum%253Aachs%26pmid%3D29466002%26genre%3Darticle%26aulast%3DMyers%26date%3D2018%26atitle%3DDevelopment%2Bof%2BPotent%2BInhibitors%2Bof%2BReceptor%2BTyrosine%2BKinases%2Bby%2BLigand-Based%2BDrug%2BDesign%2Band%2BTarget-Biased%2BPhenotypic%2BScreening%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D5%26spage%3D2104%26epage%3D2110%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291864" title="Fluorescence resonance energy transfer">Fluorescence resonance energy transfer</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/jmcmar.2018.61.issue-5/20180308/jmcmar.2018.61.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Pyrazolopyrimidines with potent antiproliferative properties were developed by an adaptive strategy that applies ligand-based design and phenotypic screening iteratively and is informed by biochemical assays. To drive development toward specific oncopathways, compounds were tested against cancer cells that overexpress, or not, AXL kinase. Identified phenotypic hits were found to inhibit oncotargets AXL, RET, and FLT3. Subsequent optimization generated antiproliferative lead compounds with unique selectivity profiles, including selective AXL inhibitors and a highly potent inhibitor of FLT3.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65805" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65805" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The R&D costs of new drug development are continuously increasing, with figures of $1.4 billion being estimated as the average out-of-pocket cost to bring a new drug into the market.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> In response to this challenging situation,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> many medicinal chemistry laboratories are exploring strategies that prioritize the search for phenotypic hits over target-based approaches to accelerate the earlier stages of drug discovery.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Such strategies are particularly well suited to find multitargeted inhibitors against difficult-to-treat malignancies due to the heterogeneous nature of these cancers.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a> Using a strategy that combines ligand-based design of focused compound libraries and phenotypic screening in an iterative manner, our lab has recently reported the discovery of novel anticancer kinase inhibitors with suitable drug-like properties in a fraction of the time and preclinical R&D costs typically required in the industry.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7,8)</a></div><div class="NLM_p">The transmembrane protein AXL is a receptor tyrosine kinase (RTK) that belongs to the TAM (TYRO3, AXL, and MER) subfamily. The oncogenic role of AXL has come under the spotlight in recent years due to its correlation with multiple cancer-promoting processes.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Incremented AXL signaling is associated with poor prognosis and drug resistance in both solid and hematological malignancies.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> This oncogenic effect can be mediated through AXL overexpression, upregulation of its ligand GAS6, or by interaction with other RTKs (e.g., EFGR, HER2, FLT3),<a onclick="showRef(event, 'ref9 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref11 ref12">(9,11,12)</a> highlighting the relevant and complex role of AXL in drug resistance to both targeted therapies and chemotherapy. While several FDA-approved kinase inhibitors have been found to inhibit AXL activity as a secondary target,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> the absence of X-ray crystallographic data for the AXL kinase has limited the development of robust structure-based drug discovery activities until very recently (the first crystal structure of the AXL kinase domain in complex with an inhibitor was reported in 2017<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>).</div><div class="NLM_p">Because of the timely need of making small molecules able to interfere with AXL oncogenic pathways, we embarked on a medchem campaign to search for phenotypically active kinase inhibitors. Inspired by published literature on inhibitors of MER (a TAM family member),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> we investigated the development of focused libraries based on a pyrazolo[3,4-<i>d</i>]pyrimidine scaffold featuring an amino group at the C6 position (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). To drive development toward the discovery of kinase inhibitors that inhibit AXL signaling, cell viability assays were performed against two cancer cell lines: a drug resistant cancer cell line expressing AXL (positive discriminating cell model) and a cancer cell line that does not express AXL (negative discriminating cell model). After two rounds of synthesis and screening, followed by kinase inhibition profiling of selected hits showing preferential activity against the AXL-expressing cell line, novel phenotypically active inhibitors of AXL, RET, and FLT3 were discovered. Further optimization enabled the discovery of several lead compounds including eSM156, an FLT3 inhibitor with single-digit nM potency and high antiproliferative activity against acute myeloid leukemia (AML) cells.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Medicinal chemistry campaign based on the cocrystal structure of <b>52</b> and MER (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2G15">2G15</a><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a>) performed by Wang and co-workers<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> for the discovery of MER inhibitor UNC569 and the 6-methylaminopyrazolo[3,4-<i>d</i>]pyrimidine scaffold explored in this work.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22873" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22873" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design, Synthesis, and Screening of Compounds <b>7a</b>–<b>j</b></h3><div class="NLM_p">Wang and co-workers<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> explored the development of trisubstituted pyrazolopyrimidines as MER inhibitors based on a docking study with the cocrystal structure of MER and derivative <b>52</b>.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Because the TAM family kinases show remarkable similarities to one another, in addition to MER, all compounds were tested against AXL and TYRO3. Exploration at the C6 position with various alkylamino groups showed that the larger the alkyl, the higher the degree of selectivity for MER over AXL. Notably, the use of a methylamino group at that position resulted in a potent inhibitor exhibiting superior potency for AXL than for MER (<b>1</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). This observation served as the starting point of the ligand-based design explored in this work.</div><div class="NLM_p">A 10-member library of derivatives of <b>1</b> was synthesized using the synthetic route described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> (see full details in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01605/suppl_file/jm7b01605_si_001.pdf" class="ext-link">Supporting Information</a>). Commercially available 6-chloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine, <b>3</b>, was treated with <i>N</i>-iodosuccinimide to iodinate the C3 position of the heterocycle (94% yield) and thus generate an activated position for Suzuki–Miyaura cross-coupling. The chloro atom at the C6 position of <b>4</b> was then substituted via a S<sub>N</sub>Ar with methylamine in THF to give <b>5</b> in moderate yield (55%). On the basis of in-house investigations<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> suggesting that the presence of a methylene-linked saturated five-membered ring at the N1 position of pyrazolopyrimidine scaffolds enhances kinase inhibition activity, intermediate <b>5</b> was alkylated via reaction with iodomethylcyclopentane or 3-bromomethyl-1-3-dioxolane to give <b>6a</b>,<b>b</b> in moderate yield (41%). 3-Aryl derivatives <b>7a</b>–<b>j</b> were prepared via Suzuki coupling in moderate to good yields (29–72%).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Four-Step Synthetic Route for the Preparation of Compounds <b>7a</b>–<b>j</b> from Commercially Available 6-Chloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine, <b>3</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Derivatives <b>7a</b>–<b>j</b> were then tested against two breast cancer cell lines: BT474 cells (AXL<sup>–</sup>), which does not express AXL, and AXL-overexpressing mouse breast cancer cells (AXL<sup>+</sup>), a cell line created in-house which is resistant to the pan-HER inhibitor sapatinib. AXL<sup>+</sup> and AXL<sup>–</sup> cells were used as a positive and negative discriminating cell model, respectively, with the aim to find compounds with preferential activity against AXL<sup>+</sup> cells and thereby bias subsequent chemical design toward the inhibition of AXL-associated oncopathways, without ruling out that further proteomics differences between these cell lines could drive the design toward additional targets. Reduction of cell proliferation was employed as the primary screening output, using the pan-RTK inhibitor foretinib (which is reported to inhibit AXL at 11 nM)<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> as a positive control. EC<sub>50</sub> values were calculated using 8-point half-log dose–response assays (0.03–100 μM) and the results plotted in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. The phenotypic screen showed that the majority of the compounds in this series were more active against AXL<sup>+</sup> cells than AXL<sup>–</sup>, with three compounds, <b>7f</b>, <b>7g</b>, and <b>7h</b>, displaying EC<sub>50</sub> values equal to or lower than 10 μM. The most potent compound from this series was <b>7f</b>, which exhibited sub-μM activity (0.83 μM) against AXL<sup>+</sup> cells and a 2-fold potency increase over the AXL<sup>–</sup> BT474 cell line (1.64 μM). Notably, the antiproliferative potency of its close analogue <b>7g</b> (containing a dioxolane group instead of a cyclopentane) was an order of magnitude lower, indicating that the presence of one or more oxygen atoms in that moiety negatively affects activity. Because of the high potency of <b>7f</b> and its promising EC<sub>50</sub>(AXL<sup>–</sup>)/EC<sub>50</sub>(AXL<sup>+</sup>) ratio, the 6-(1-piperazinyl)-pyrid-3-yl group of <b>7f</b> was chosen as the C3 motif for the preparation of a second library of pyrazolopyrimidines.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. EC<sub>50</sub> values of <b>7a</b>–<b>j</b> and the positive control foretinib against AXL<sup>–</sup> (red) and AXL<sup>+</sup> (blue) cells. Cell viability assay: PrestoBlue reagent at day 5. Error bars: ±SD from <i>n</i> = 2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Design, Synthesis, and Screening of Compounds <b>10a</b>–<b>g</b></h3><div class="NLM_p">The second library was designed to explore the incorporation of more complex moieties at the N1 position of the pyrazolopyrimidine. Because the presence of a methylene-linked five-membered ring at that position generated compounds with high activity and the 1,3-dioxolanylmethyl group was found to be suboptimal, other heteroaromatic rings were considered. To the best of our knowledge, the introduction of substituted triazolylmethyl groups at the N1 position of the scaffold studied in this work have not yet been reported. A substituted 1,2,3-triazole group (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) was thus selected to facilitate the preparation of different analogues by click chemistry, study novel structure–activity relationships (SAR), and add freedom-to-operate to the chemical space under exploration. The alkyne handle was introduced by alkylation of intermediate <b>5</b> with propargyl bromide, giving <i>N</i>-propargyl derivative <b>8</b> in 23% yield. Copper-catalyzed azide–alkyne cycloadditions were carried out with seven different organic azides using copper iodide, sodium ascorbate, and triethylamine to give <b>9a</b>–<b>g</b> in good yields (>66%). Palladium-catalyzed Suzuki cross-coupling of the triazole-containing derivatives <b>9a</b>–<b>g</b> with 6-(1-piperazinyl)pyridyl-4-boronic acid pinacol ester provided final compounds <b>10a</b>–<b>g</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route for the Preparation of Triazole-Containing Compounds <b>10a</b>–<b>g</b> from Intermediate <b>5</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antiproliferative activity of <b>10a</b>–<b>g</b> was then tested against AXL<sup>–</sup> and AXL<sup>+</sup> cells. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, the most potent derivatives of this series were <b>10a</b> (R = benzyl) and <b>10d</b> (R = 2-(methoxycarbonyl)thienyl)), both of which exhibited superior antiproliferative activity against AXL<sup>+</sup> cells. However, the potency of <b>10a</b> and <b>10d</b> was lower than that of the phenotypic hit <b>7f</b>. The introduction of aliphatic rings (<b>10b</b>,<b>c</b>) at the 3′ position of the triazole ring led to a dramatic reduction in potency. The direct linkage of phenyl rings to the 3′ position of the triazole (<b>10e</b>–<b>g</b>) did not improve activity over the benzyl-containing derivative <b>10a</b>.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. EC<sub>50</sub> values of <b>10a</b>–<b>g</b> and reference hit <b>7f</b> against AXL<sup>–</sup> (red) and AXL<sup>+</sup> (blue) cells. Cell viability assay: PrestoBlue reagent at day 5. Error bars: ±SD from <i>n</i> = 2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To shed light over the pharmacodynamic profile responsible for the antiproliferative properties of phenotypic hits <b>7f</b>,<b>g</b>,<b>h</b> and <b>10a</b>,<b>d</b>, kinase inhibition activities were evaluated against a panel of 12 protein kinases. The panel, which included the three members of the TAM family, was selected based on the selectivity profile frequently found for other AXL inhibitors.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Kinase inhibition studies were performed by Reaction Biology Corporation, USA, by measuring <sup>33</sup>P incorporation on the corresponding kinase substrate relative to DMSO. Calculated half-maximal inhibitory concentration (IC<sub>50</sub>) values are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values (in μM) for <b>7f</b>,<b>g</b>,<b>h</b> and <b>10a</b>,<b>d</b> against a Selection of Recombinant Tyrosine Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase/hit</th><th class="colsep0 rowsep0" align="center"><b>7f</b></th><th class="colsep0 rowsep0" align="center"><b>7g</b></th><th class="colsep0 rowsep0" align="center"><b>7h</b></th><th class="colsep0 rowsep0" align="center"><b>10a</b></th><th class="colsep0 rowsep0" align="center"><b>10d</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AKT</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora A</td><td class="colsep0 rowsep0" align="center">0.16</td><td class="colsep0 rowsep0" align="center">0.66</td><td class="colsep0 rowsep0" align="center">0.56</td><td class="colsep0 rowsep0" align="center">1.8</td><td class="colsep0 rowsep0" align="center">0.79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AXL<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><b>0.12</b></td><td class="colsep0 rowsep0" align="center"><b>0.53</b></td><td class="colsep0 rowsep0" align="center"><b>1.3</b></td><td class="colsep0 rowsep0" align="center"><b>0.40</b></td><td class="colsep0 rowsep0" align="center"><b>0.78</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KIT</td><td class="colsep0 rowsep0" align="center">1.1</td><td class="colsep0 rowsep0" align="center">7.5</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MER<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">0.64</td><td class="colsep0 rowsep0" align="center">6.2</td><td class="colsep0 rowsep0" align="center">8.7</td><td class="colsep0 rowsep0" align="center">2.3</td><td class="colsep0 rowsep0" align="center">8.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MET</td><td class="colsep0 rowsep0" align="center">2.1</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SRC</td><td class="colsep0 rowsep0" align="center">1.1</td><td class="colsep0 rowsep0" align="center">0.89</td><td class="colsep0 rowsep0" align="center">7.2</td><td class="colsep0 rowsep0" align="center">1.0</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT3</td><td class="colsep0 rowsep0" align="center"><b>0.02</b></td><td class="colsep0 rowsep0" align="center"><b>0.10</b></td><td class="colsep0 rowsep0" align="center"><b>0.25</b></td><td class="colsep0 rowsep0" align="center"><b>0.53</b></td><td class="colsep0 rowsep0" align="center"><b>0.86</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR2</td><td class="colsep0 rowsep0" align="center">0.69</td><td class="colsep0 rowsep0" align="center">4.5</td><td class="colsep0 rowsep0" align="center">7.5</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mTOR</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET</td><td class="colsep0 rowsep0" align="center"><b>0.05</b></td><td class="colsep0 rowsep0" align="center"><b>0.16</b></td><td class="colsep0 rowsep0" align="center"><b>1.2</b></td><td class="colsep0 rowsep0" align="center"><b>0.60</b></td><td class="colsep0 rowsep0" align="center"><b>0.43</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TYRO3<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Member of TAM subfamily.</p></div></div></div><div class="NLM_p last">The results from the kinase screenings confirmed that the most potent phenotypic hits from both libraries inhibited AXL kinase activity at low μM to sub-μM levels. However, much like many reported AXL inhibitors,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> in most cases the primary target was not the AXL kinase, with FLT3 and RET being the most potently inhibited kinases across the screen. Of note, all the hits showed selectivity over the TAM family members TYRO3 and MER, proving the importance of using a methylamino group at the C6 position of the scaffold to achieve subfamily selectivity. In agreement with the cell-based assays, derivative <b>7f</b> displayed the greatest activity against AXL, FLT3, and RET: 0.12, 0.02, and 0.05 μM, respectively. Arguably, the most interesting hit from this screening was the 3′-benzyltriazolyl derivative <b>10a</b>, which exhibited the second highest potency against AXL (0.4 μM) and, importantly, was the only inhibitor to display superior activity for AXL than for FLT3 and RET. This preferential selectivity against AXL was not observed with the close derivative <b>10d</b>, suggesting that the flexible benzyl group provides a certain degree of conformational freedom that is advantageous for binding to the AXL protein but less favorable for FLT3 and RET.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Design, Synthesis, and Screening of Compounds <b>12a</b>–<b>f</b></h3><div class="NLM_p">On the basis of the cell assays and the kinase screening, six new derivatives of <b>10a</b> were prepared to search for improved AXL inhibition. <b>12a</b>–<b>f</b> were prepared in moderate yields (27–58%) by Suzuki cross-coupling of intermediate <b>9a</b> with six different arylboronate/boronic acids. The diversity of the moieties incorporated at the C3 position (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) aimed to evaluate the importance of the H-donor and acceptors of the 6-(1-piperazinyl)-pyrid-3-yl moiety of <b>10a</b>.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structure, molecular weight (MW), and cLogP of derivatives <b>12a</b>–<b>f</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Following the protocol described above, <b>12a</b>–<b>f</b> were tested against AXL<sup>–</sup> and AXL<sup>+</sup> cells and the resulting EC<sub>50</sub> values plotted in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. Whereas none of the new analogues improved the activity of <b>10a</b> against the AXL<sup>+</sup> cell line, <b>12b</b> showed a superior EC<sub>50</sub>(AXL<sup>–</sup>)/EC<sub>50</sub>(AXL<sup>+</sup>) ratio, potentially indicating enhanced AXL selectivity. Interestingly, the seemly minor substitution of the pyridine N atom by a CH led to an inversion of the cell activity ratio, pointing out off-target effects. It was also noticeable that the attachment of large groups at the piperazinyl NH (<b>12c</b>,<b>d</b>) reduced antiproliferative activity against the AXL<sup>+</sup> cell line. The substitution of the pyperazinyl group by methylamino (<b>12f</b>) resulted in a completely inactive derivative.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. EC<sub>50</sub> values of <b>12a</b>–<b>f</b> and reference hit <b>10a</b> against AXL<sup>–</sup> (red) and AXL<sup>+</sup> (blue) cells. Cell viability assay: PrestoBlue reagent at day 5. Error bars: ±SD from <i>n</i> = 2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To understand how these structural changes had affected the kinase selectivity of the new compounds, <b>12a</b>–<b>d</b> were screened against the 12-member panel of kinases used for previous hits. As before, kinase inhibition screenings were performed using radioisotope based methods by Reaction Biology Corporation. Inhibitor BGB324, which is widely considered a selective AXL inhibitor (even if the available kinase selectivity information is limited)<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and the first one to enter clinical trials based on its AXL inhibitory properties,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> was used as a positive control. Calculated IC<sub>50</sub> values are shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. IC<sub>50</sub> Values (in μM) for <b>12a</b>–<b>d</b> and BGB324 against a Selection of Recombinant Tyrosine Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase/hit</th><th class="colsep0 rowsep0" align="center"><b>12a</b></th><th class="colsep0 rowsep0" align="center"><b>12b</b></th><th class="colsep0 rowsep0" align="center"><b>12c</b></th><th class="colsep0 rowsep0" align="center"><b>12d</b></th><th class="colsep0 rowsep0" align="center"><b>BGB324</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AKT</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">1.9</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora A</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.73</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.84</td><td class="colsep0 rowsep0" align="center">0.026</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AXL<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><b>>10</b></td><td class="colsep0 rowsep0" align="center"><b>0.38</b></td><td class="colsep0 rowsep0" align="center"><b>>10</b></td><td class="colsep0 rowsep0" align="center"><b>0.76</b></td><td class="colsep0 rowsep0" align="center"><b>0.0007</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KIT</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MER<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">2.0</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">5.4</td><td class="colsep0 rowsep0" align="center">0.015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MET</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">6.3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SRC</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">8.3</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.037</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT3</td><td class="colsep0 rowsep0" align="center"><b>>10</b></td><td class="colsep0 rowsep0" align="center"><b>0.70</b></td><td class="colsep0 rowsep0" align="center"><b>>10</b></td><td class="colsep0 rowsep0" align="center"><b>1.2</b></td><td class="colsep0 rowsep0" align="center"><b>0.0009</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR2</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">7.6</td><td class="colsep0 rowsep0" align="center">7.7</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mTOR</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET</td><td class="colsep0 rowsep0" align="center"><b>>10</b></td><td class="colsep0 rowsep0" align="center"><b>0.90</b></td><td class="colsep0 rowsep0" align="center"><b>6.2</b></td><td class="colsep0 rowsep0" align="center"><b>4.0</b></td><td class="colsep0 rowsep0" align="center"><b>0.003</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TYRO3<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">1.9</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.017</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Member of TAM subfamily.</p></div></div></div><div class="NLM_p last">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, derivative <b>12b</b> exhibited superior AXL inhibition (0.38 μM) and an increased degree of selectivity over FLT3 and RET in comparison to reference hit <b>10a</b>. In silico studies provided preliminary insights into the binding mode of 12b in AXL and RET (see the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01605/suppl_file/jm7b01605_si_001.pdf" class="ext-link">Supporting Information</a>). It is important to note that <b>10a</b> displayed higher antiproliferative activity against AXL<sup>+</sup> cells (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), which may be caused by superior cell permeant properties or by unidentified off-target activities. The rest of the compounds of this series were not as potent as <b>12b</b> and showed poorer selectivity profiles. Derivative <b>12a</b>, which was previously found to display a EC<sub>50</sub>(AXL<sup>–</sup>)/EC<sub>50</sub>(AXL<sup>+</sup>) < 1, did not elicit inhibition to any of the kinases tested in the screen, further proof that its “inversed” antiproliferative properties are a consequence of targeting proteins unrelated to AXL-associated oncopathways. Remarkably, the screening revealed that the supposedly AXL-selective inhibitor BGB324 actually inhibits both AXL and FLT3 kinases with equivalent potency. This information, which to our knowledge is reported herein for the first time, further illustrates the difficulty of designing selective AXL inhibitors due to the structural similarities of the catalytic domains of AXL and other RTKs (e.g., FLT3 and RET). Furthermore, it underlines the value of discovering cell-active AXL kinase-selective inhibitors such as <b>10a</b> and <b>12b</b>.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Design, Synthesis, and Screening of Compounds <b>13a</b>–<b>d</b></h3><div class="NLM_p">At this point of the campaign, only <b>7f</b> exhibited sub-μM antiproliferative activity against the AXL<sup>+</sup> breast cancer cell model. According to the kinase screen (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), <b>7f</b> inhibited AXL with high potency (0.12 μM) and displayed even higher potency against FLT3 and RET (0.02 and 0.05 μM, respectively). These two RTKs have been strongly linked to various malignancies. FLT3 is upregulated in acute lymphoblastic leukemia,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and the <i>FLT3-ITD</i> mutation is found in 30–40% of adult AML patients and associated with low survival rates. Because of its prognostic importance, the WHO recommends ascertaining the mutational status of <i>FLT3</i> in AML patients.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> RET has been linked to numerous cancer types, including pancreatic,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> breast cancer,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and AML.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> RET is associated with metastasis and cancer relapse, being a predictor of acquired resistance and poor patient prognosis. Because AXL has also been associated with AML,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> following the lab’s ethos of evolving development in response to inhibitors’ properties to accelerate the discovery of lead compounds,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> the program was steered toward AML.</div><div class="NLM_p">Four derivatives featuring a cyclopentylmethyl moiety at N1 position (as <b>7f</b>) were prepared by Suzuki coupling of intermediate <b>6a</b> with the corresponding arylboronate/boronic acids. The substituents at the C3 position of <b>13b</b>–<b>d</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) were the same as the ones previously used for <b>12b</b>–<b>d</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). However, because derivative <b>12a</b> displayed no inhibition of AXL, FLT3, or RET (see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), a <i>N</i>-methyl derivative of the 4-pyperazinylphenyl group used in <b>12a</b> was incorporated at C3 on derivative <b>13a</b>.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structure, MW, and cLogP of derivatives <b>13a</b>–<b>d</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The antiproliferative properties of <b>13a</b>–<b>d</b> were tested against the AML cell lines MV4-11 (homozygous <i>FLT3</i>/<i>ITD</i> mutant<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a>) and MOLM-13 (heterozygous for <i>FLT3</i>/<i>ITD</i> mutation<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a>), using the dual AXL/FLT3 inhibitor BGB324 as a positive control. As shown in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, derivatives <b>13a</b> and <b>13b</b> displayed sub-μM EC<sub>50</sub> values, highlighting the potent antiproliferative activity of derivative <b>13a</b>, which displayed in both cell lines superior potency than BGB324, an inhibitor that is currently in clinical development for the treatment of AML.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. EC<sub>50</sub> values of <b>13a</b>–<b>d</b> and BGB324 against MV4-11 and MOLM-13 cells. Cell viability assay: PrestoBlue reagent at day 5. Error bars: ±SD from <i>n</i> = 2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given the fairly similar MW and cLogP of derivatives <b>13a</b>–<b>d</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), it was anticipated that the different antiproliferative activity observed for each member of this series were caused by variations in on-target potency. Biochemical assays were then performed for <b>13a</b>–<b>d</b> against the 12 recombinant kinases tested before. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, the analogues’ activity against FLT3 correlated with their antiproliferative activity in AML cells. Derivative <b>13a</b>, the most potent inhibitor of the series, displayed 1.4 nM activity (IC<sub>50</sub>) against FLT3 and IC<sub>50</sub> values ranging from 6 to 13 nM for Aurora A, RET, and AXL. To attain a more detailed picture of the selectivity of the best hits, <b>13a</b>,<b>b</b> and BGB324 were further screened against a selection of eight kinases commonly inhibited by FLT3 inhibitors: ALK, Aurora B, DDR1, EGFR, PDGFRa, and FLT3 mutants FLT ITD and FLT3 835Y. Derivative <b>13a</b> showed selectivity over EGFR and PDGFRa, exhibited moderate potency against Aurora B and DDR1, and high potency against ALK, FLT ITD, and FLT3 835Y. The same trend was observed for <b>13b</b>, although displaying a potency reduction of 4–8-fold relative to <b>13a</b>. In comparison with the clinical candidate BGB324, the potent inhibitor <b>13a</b> displayed 2-fold lower potency against RET, FLT3, and its mutants and 4-fold superior potency against Aurora A. However, it exhibited a 20-fold reduction in activity against AXL. It is important to note that <b>13a</b> showed superior potency against MV4-11 and MOLM-13 cells, which may be due to improved membrane permeant properties or to the inhibition of other targets such as Aurora A.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. IC<sub>50</sub> Values (in μM) for <b>13a</b>–<b>d</b> and BGB324 against a Selection of Recombinant Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase/hit</th><th class="colsep0 rowsep0" align="center"><b>13a</b></th><th class="colsep0 rowsep0" align="center"><b>13b</b></th><th class="colsep0 rowsep0" align="center"><b>13c</b></th><th class="colsep0 rowsep0" align="center"><b>13d</b></th><th class="colsep0 rowsep0" align="center"><b>BGB324</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AKT</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ALK</td><td class="colsep0 rowsep0" align="center">0.05</td><td class="colsep0 rowsep0" align="center">0.19</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">0.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora A</td><td class="colsep0 rowsep0" align="center">0.006</td><td class="colsep0 rowsep0" align="center">0.03</td><td class="colsep0 rowsep0" align="center">0.28</td><td class="colsep0 rowsep0" align="center">0.61</td><td class="colsep0 rowsep0" align="center">0.026</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aurora B</td><td class="colsep0 rowsep0" align="center">0.1</td><td class="colsep0 rowsep0" align="center">0.17</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AXL<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center"><b>0.013</b></td><td class="colsep0 rowsep0" align="center"><b>0.07</b></td><td class="colsep0 rowsep0" align="center"><b>0.26</b></td><td class="colsep0 rowsep0" align="center"><b>7.2</b></td><td class="colsep0 rowsep0" align="center"><b>0.0007</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DDR1</td><td class="colsep0 rowsep0" align="center">0.035</td><td class="colsep0 rowsep0" align="center">0.1</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EFGR</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">3.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KIT</td><td class="colsep0 rowsep0" align="center">0.068</td><td class="colsep0 rowsep0" align="center">0.36</td><td class="colsep0 rowsep0" align="center">1.8</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MER<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">0.092</td><td class="colsep0 rowsep0" align="center">0.48</td><td class="colsep0 rowsep0" align="center">2.5</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MET</td><td class="colsep0 rowsep0" align="center">0.42</td><td class="colsep0 rowsep0" align="center">3.5</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SRC</td><td class="colsep0 rowsep0" align="center">0.093</td><td class="colsep0 rowsep0" align="center">0.8</td><td class="colsep0 rowsep0" align="center">3.6</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.037</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT3</td><td class="colsep0 rowsep0" align="center"><b>0.0014</b></td><td class="colsep0 rowsep0" align="center"><b>0.008</b></td><td class="colsep0 rowsep0" align="center"><b>0.1</b></td><td class="colsep0 rowsep0" align="center"><b>0.3</b></td><td class="colsep0 rowsep0" align="center"><b>0.0009</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT3 ITD</td><td class="colsep0 rowsep0" align="center"><b>0.011</b></td><td class="colsep0 rowsep0" align="center"><b>0.03</b></td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center"><b>0.006</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT3 D835Y</td><td class="colsep0 rowsep0" align="center"><b>0.004</b></td><td class="colsep0 rowsep0" align="center"><b>0.012</b></td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center"><b>0.002</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRa</td><td class="colsep0 rowsep0" align="center">0.37</td><td class="colsep0 rowsep0" align="center">0.99</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR2</td><td class="colsep0 rowsep0" align="center">0.066</td><td class="colsep0 rowsep0" align="center">0.40</td><td class="colsep0 rowsep0" align="center">1.9</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mTOR</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RET</td><td class="colsep0 rowsep0" align="center"><b>0.006</b></td><td class="colsep0 rowsep0" align="center"><b>0.06</b></td><td class="colsep0 rowsep0" align="center"><b>0.44</b></td><td class="colsep0 rowsep0" align="center"><b>>10</b></td><td class="colsep0 rowsep0" align="center"><b>0.003</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TYRO3<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">0.6</td><td class="colsep0 rowsep0" align="center">3.67</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">0.017</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Member of TAM subfamily. ND: not determined.</p></div></div></div><div class="NLM_p">Because of the high potency of <b>13a</b> in vitro and in cells, an expanded kinome inhibition study was performed (single dose of 1 μM, in duplicate) against 369 wild-type kinases. Enzymatic inhibition was compared to DMSO (= 0% inhibition) and averaged results plotted in a kinome phylogenetic tree with a 65% cutoff value using TREEspot from DiscoveRx (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>; values listed in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b01605/suppl_file/jm7b01605_si_001.pdf" class="ext-link">Table 1</a>). The study gave a <i>S</i>-score of 0.22 and, although not as potent as FLT3, most hits (>65% inhibition) belonged to the tyrosine kinase family. Besides FLT3, the tyrosine kinase JAK3 was also inhibited at levels superior to 98%. This is relevant as <i>JAK3</i> is a proto-oncogene associated with different leukemias.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Other strongly inhibited proteins from different families included ARK5, MAP4K family kinases, LRRK2, MINK1, RSK4, TNIK, TRKC, and TYK2.</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Map of the human kinome screened for <b>13a</b> at 1 μM. Green circles denote <65% inhibition. Red circles denote >65% inhibition (>98% for the largest one).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07757" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07757" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Using an adaptive approach that combines ligand-based design of small libraries of pyrazolopyrimidines, target-informative cancer cell assays, and kinase screenings, two selective AXL inhibitors and a potent FLT3 inhibitor have been developed. The discovery of cell active AXL inhibitors <b>10a</b> (eSM119) and <b>12b</b> (eSM134) is relevant due to the lack of inhibitors that targets AXL with selectivity over TAM family members MER and TYRO3 and other RTKs (e.g., RET, FLT3). The merit of developing these lead compounds is further highlighted by the finding that BGB324, the only inhibitor in clinical development presumed to be selective for AXL,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> is actually a dual AXL/FLT3 inhibitor. By steering the program toward AML, the potent FLT3 inhibitor <b>13a</b> (eSM156) was discovered, which displays single-digit nM IC<sub>50</sub> against FLT3 and its mutants and low sub-μM EC<sub>50</sub> against AML cells. Given its remarkable biological properties, eSM156 represents an attractive lead for future optimization against FLT3 and other proteins discovered in the kinome screening.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13010" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13010" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General</h3><div class="NLM_p last">Chemicals were purchased from Fisher, Sigma-Aldrich, or VWR. Microwave reactions were carried out in a Biotage Initiator. NMR spectra were recorded at rt on a 500 MHz Bruker Avance III spectrometer. Chemical shifts are reported in ppm relative to solvent peak. Analytical TLC was performed on Merck TLC Silica Gel 60 F254 plates and visualized by UV light. Purifications were performed by flash chromatography with commercially available silica gel and solvents. All compounds used in the biological screenings were determined to be >95% pure by HPLC.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Synthesis of 3-Iodo-<i>N</i>-methyl-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-6-amine (<b>5</b>)</h3><div class="NLM_p last"><i>N</i>-Iodosuccinimide (1.9 g) was added to a suspension of 6-chloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine (1.0 g) in DMF (15 mL) and microwave-heated at 120 °C for 1 h. H<sub>2</sub>O (50 mL) and EtOAc (50 mL × 3) were added, and the organic layers were collected, washed with H<sub>2</sub>O (30 mL × 2) and brine (20 mL), dried over anhydrous MgSO<sub>4</sub>, and concentrated in vacuo. Flash chromatography (MeOH/DCM 0–2%) yielded <b>4</b> as a yellow solid (1.64 g, 91%). <sup>1</sup>H NMR (500 MHz, DMSO) δ 14.64 (1 H, s, NH), 9.02 (1 H, s, CH). LRMS (+ve) <i>m</i>/<i>z</i> [M + 1] 281.00. <b>4</b> (500 mg) was dissolved in THF (3 mL), added to CH<sub>3</sub>NH<sub>2</sub> (12 mL), and microwave heated at 150 °C for 1 h. A white solid precipitated out, dried by vacuum filtration, and washed with H<sub>2</sub>O (3 mL × 3) to yield <b>5</b> as a beige solid (270 mg, 55%). <sup>1</sup>H NMR (500 MHz, DMSO) δ 12.61 (1 H, s), 8.46 (1 H, s), 7.54 (1 H, s), 2.83 (3 H, d, <i>J</i> = 3.5). <sup>13</sup>C NMR (126 MHz, DMSO) δ 162.7, 157.1, 153.9, 134.2, 93.3, 67.5, 28.5. HRMS (ESI +ve) <i>m</i>/<i>z</i> [M + 1] 275.9737.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Synthesis of 1-(Cyclopentylmethyl)-<i>N</i>-methyl-3-[4-(4-methylpiperazin-1-yl)phenyl]-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-6-amine (<b>13a</b>)</h3><div class="NLM_p last"><b>5</b> (265 mg) in DMF (3 mL) was added NaH (34 mg) and stirred until gas evolution subsided. (Iodomethyl)cyclopentane (0.182 mL) was added dropwise and the resulting mix microwave-heated for 1.5 h at 150 °C. H<sub>2</sub>O (50 mL) and EtOAc (50 mL × 3) were added, and the organic layers were collected, washed with water (30 mL × 2) and brine (20 mL), dried over anhydrous MgSO<sub>4</sub>, and concentrated in vacuo. The crude was purified by flash chromatography MeOH/DCM (0–5%) to give <b>6a</b> as a yellow solid (133 mg, 40%). <sup>1</sup>H NMR (500 MHz, DMSO) δ 8.44 (1 H, s, NH), 7.61 (1 H, s), 4.11 (2 H, s), 2.86 (3 H, s), 1.65–1.21 (9 H, m). <sup>13</sup>C NMR (126 MHz, DMSO) δ 162.5, 155.8, 154.2, 112.0, 92.3, 50.7, 32.1, 30.1, 28.3, 24.8. HRMS (ESI +ve) <i>m</i>/<i>z</i> [M + 1] 358.0523. <b>6a</b> (60 mg), 4-(4-methylpiperazin-1-yl)phenylboronic acid (76 mg), K<sub>2</sub>CO<sub>3</sub> (34 mg), PPh<sub>3</sub> (20%mol), and Pd(OAc)<sub>2</sub> (5%mol) were dissolved in 9:1 dioxane/water (5 mL) and microwave-heated at 120 °C for 1 h. H<sub>2</sub>O (50 mL) and EtOAc (50 mL × 3) were added, and the organic layers were collected, washed with water (30 mL × 2) and brine (20 mL), dried over anhydrous MgSO<sub>4</sub>, and concentrated in vacuo. The crude was purified by flash chromatography (MeOH/DCM 0–10%) to yield <b>13a</b> as a yellow solid (31 mg, 45%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.93 (1 H, s), 7.83 (2 H, m), 7.04 (2 H, m), 4.25 (2 H, d, <i>J</i> = 7.5,), 3.34 (5 H, m), 3.09 (3 H, d, <i>J</i> = 5.0), 2.65 (6 H, d, <i>J</i> = 6.0), 2.41 (4 H, s), 1.41 (2 H, d, <i>J</i> = 5.5), 1.28 (3 H, s). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 161.4, 156.0, 153.5, 151.3, 143.9, 127.8, 115.9, 54.9, 50.8, 48.5, 46.1, 40.2, 30.3, 28.6, 24.9. HRMS (ESI +ve) <i>m</i>/<i>z</i> [M + 1] 406.2132.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01605" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30825" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30825" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01605" class="ext-link">10.1021/acs.jmedchem.7b01605</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Characterization of compounds, docking studies, and biological methods (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01605/suppl_file/jm7b01605_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01605/suppl_file/jm7b01605_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01605/suppl_file/jm7b01605_si_001.pdf">jm7b01605_si_001.pdf (1.21 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01605/suppl_file/jm7b01605_si_002.csv">jm7b01605_si_002.csv (2.84 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01605" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87421" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87421" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Asier Unciti-Broceta</span> - <span class="hlFld-Affiliation affiliation">Cancer
Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular
Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1029-2855" title="Orcid link">http://orcid.org/0000-0003-1029-2855</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0647756f6374285368656f726f2b44746965637267466f616b6b28636228676528736d"><span class="__cf_email__" data-cfemail="5b1a28323e29750e3538322f3276192934383e2f3a1b323c3636753e3f753a38752e30">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samuel
H. Myers</span> - <span class="hlFld-Affiliation affiliation">Cancer
Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular
Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carolin Temps</span> - <span class="hlFld-Affiliation affiliation">Cancer
Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular
Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas R. Houston</span> - <span class="hlFld-Affiliation affiliation">Institute
of Quantitative Biology, Biochemistry and Biotechnology, University of Edinburgh, Edinburgh EH9 3BF, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Valerie G. Brunton</span> - <span class="hlFld-Affiliation affiliation">Cancer
Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular
Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>All authors approved the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e2394-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05111" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05111" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Scottish Power and CRUK for funding. C.T. thanks the CMVM for a Principal’s Scholarship.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">S<sub>N</sub>Ar</td><td class="NLM_def"><p class="first last">nucleophilic aromatic substitution</p></td></tr><tr><td class="NLM_term">TAM</td><td class="NLM_def"><p class="first last">TYRO3, AXL and MER</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41308" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41308" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 25 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avorn, J.</span></span> <span> </span><span class="NLM_article-title">The $2.6 Billion pill — methodologic and policy considerations</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1877</span>– <span class="NLM_lpage">1879</span>, <span class="refDoi"> DOI: 10.1056/NEJMp1500848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1056%2FNEJMp1500848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=25970049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlehs73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1877-1879&author=J.+Avorn&title=The+%242.6+Billion+pill+%E2%80%94+methodologic+and+policy+considerations&doi=10.1056%2FNEJMp1500848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The $2.6 billion pill - methodologic and policy considerations</span></div><div class="casAuthors">Avorn, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1877-1879</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwRcSjishmd7Vg90H21EOLACvtfcHk0lg_GRwHO218NQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlehs73J&md5=6a4f7872393d76f1a9748f4be5968565</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1500848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1500848%26sid%3Dliteratum%253Aachs%26aulast%3DAvorn%26aufirst%3DJ.%26atitle%3DThe%2520%25242.6%2520Billion%2520pill%2520%25E2%2580%2594%2520methodologic%2520and%2520policy%2520considerations%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1877%26epage%3D1879%26doi%3D10.1056%2FNEJMp1500848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DiMasi, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R. W.</span></span> <span> </span><span class="NLM_article-title">Innovation in the pharmaceutical industry: New estimates of R&D costs</span>. <i>J. Health. Econ.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.jhealeco.2016.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1016%2Fj.jhealeco.2016.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=26928437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A280%3ADC%252BC28jls1egsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2016&pages=20-33&author=J.+A.+DiMasiauthor=H.+G.+Grabowskiauthor=R.+W.+Hansen&title=Innovation+in+the+pharmaceutical+industry%3A+New+estimates+of+R%26D+costs&doi=10.1016%2Fj.jhealeco.2016.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Innovation in the pharmaceutical industry: New estimates of R&D costs</span></div><div class="casAuthors">DiMasi Joseph A; Grabowski Henry G; Hansen Ronald W</div><div class="citationInfo"><span class="NLM_cas:title">Journal of health economics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The research and development costs of 106 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms.  These data were used to estimate the average pre-tax cost of new drug and biologics development.  The costs of compounds abandoned during testing were linked to the costs of compounds that obtained marketing approval.  The estimated average out-of-pocket cost per approved new compound is $1395 million (2013 dollars).  Capitalizing out-of-pocket costs to the point of marketing approval at a real discount rate of 10.5% yields a total pre-approval cost estimate of $2558 million (2013 dollars).  When compared to the results of the previous study in this series, total capitalized costs were shown to have increased at an annual rate of 8.5% above general price inflation.  Adding an estimate of post-approval R&D costs increases the cost estimate to $2870 million (2013 dollars).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ64KxQIdSPM8K3uFsUIZtkfW6udTcc2eYKvhC4z0h2Crntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jls1egsw%253D%253D&md5=a78649853406ddbfe54abb0052ca964b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.jhealeco.2016.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhealeco.2016.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DDiMasi%26aufirst%3DJ.%2BA.%26aulast%3DGrabowski%26aufirst%3DH.%2BG.%26aulast%3DHansen%26aufirst%3DR.%2BW.%26atitle%3DInnovation%2520in%2520the%2520pharmaceutical%2520industry%253A%2520New%2520estimates%2520of%2520R%2526D%2520costs%26jtitle%3DJ.%2520Health.%2520Econ.%26date%3D2016%26volume%3D47%26spage%3D20%26epage%3D33%26doi%3D10.1016%2Fj.jhealeco.2016.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kola, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landis, J.</span></span> <span> </span><span class="NLM_article-title">Can the pharmaceutical industry reduce attrition rates?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1038/nrd1470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1038%2Fnrd1470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=15286737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-716&author=I.+Kolaauthor=J.+Landis&title=Can+the+pharmaceutical+industry+reduce+attrition+rates%3F&doi=10.1038%2Fnrd1470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Opinion: Can the pharmaceutical industry reduce attrition rates?</span></div><div class="casAuthors">Kola, Ismail; Landis, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-716</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry faces considerable challenges, both politically and fiscally.  Politically, governments around the world are trying to contain costs and, as health care budgets constitute a very significant part of governmental spending, these costs are the subject of intense scrutiny.  In the United States, drug costs are also the subject of intense political discourse.  This article deals with the fiscal pressures that face the industry from the perspective of R&D.  What impinges on productivity How can we improve current reduced R&D productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruAlrpFPFmiLVg90H21EOLACvtfcHk0lhb0tosdtAWpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D&md5=f9025c13a1506f607aaf68415570ed01</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd1470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1470%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DCan%2520the%2520pharmaceutical%2520industry%2520reduce%2520attrition%2520rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D711%26epage%3D716%26doi%3D10.1038%2Fnrd1470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlik, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moxham, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomandl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sall, D. J.</span></span> <span> </span><span class="NLM_article-title">Modern phenotypic drug discovery is a viable, neoclassic pharma strategy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4527</span>– <span class="NLM_lpage">4538</span>, <span class="refDoi"> DOI: 10.1021/jm201649s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201649s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1OitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4527-4538&author=J.+A.+Leeauthor=M.+T.+Uhlikauthor=C.+M.+Moxhamauthor=D.+Tomandlauthor=D.+J.+Sall&title=Modern+phenotypic+drug+discovery+is+a+viable%2C+neoclassic+pharma+strategy&doi=10.1021%2Fjm201649s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy</span></div><div class="casAuthors">Lee, Jonathan A.; Uhlik, Mark T.; Moxham, Christopher M.; Tomandl, Dirk; Sall, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4527-4538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pharmaceutical industry (Pharma) is currently facing unprecedented challenges.  In addn. to strategic patent expirations, the rate of drug launches has been essentially const. for 60 years with overall productivity falling since the 1970s.  Similarly, the appearance of novel targets to FDA approved drugs, a measure of industry innovation, has not dramatically improved since the 1980s.  Although Pharma productivity is a multifaceted problem, detailed analyses of comprehensive, industry-wide data indicate that late stage clin. failures are a major contributor that has been attributed to poor target validation (TV) and the lack of predictive biomarkers that translate to the clinic.  In the spirit of "reinventing innovation" Pharma needs to introspectively identify areas for improvement.  This communication considers how choices in drug screening strategies may relate to target validation issues and influence the probability of identifying novel medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8CcODiYYNgLVg90H21EOLACvtfcHk0lilt2HuzRL9AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1OitLs%253D&md5=1937641b632e348d7566c016ca4cf51d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm201649s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201649s%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BA.%26aulast%3DUhlik%26aufirst%3DM.%2BT.%26aulast%3DMoxham%26aufirst%3DC.%2BM.%26aulast%3DTomandl%26aufirst%3DD.%26aulast%3DSall%26aufirst%3DD.%2BJ.%26atitle%3DModern%2520phenotypic%2520drug%2520discovery%2520is%2520a%2520viable%252C%2520neoclassic%2520pharma%2520strategy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4527%26epage%3D4538%26doi%3D10.1021%2Fjm201649s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Targeting the cancer kinome through polypharmacology</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&author=Z.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+cancer+kinome+through+polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0lilt2HuzRL9AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520cancer%2520kinome%2520through%2520polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carragher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unciti-Broceta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, D.</span></span> <span> </span><span class="NLM_article-title">Advancing drug discovery towards more agile development of targeted combination therapies</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.4155%2Ffmc.11.169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=22168166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ahtb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=87-105&author=N.+Carragherauthor=A.+Unciti-Brocetaauthor=D.+Cameron&title=Advancing+drug+discovery+towards+more+agile+development+of+targeted+combination+therapies&doi=10.4155%2Ffmc.11.169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing cancer drug discovery towards more agile development of targeted combination therapies</span></div><div class="casAuthors">Carragher, Neil O.; Unciti-Broceta, Asier; Cameron, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-105</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Current drug-discovery strategies are typically target-centric'' and are based upon high-throughput screening of large chem. libraries against nominated targets and a selection of lead compds. with optimized on-target'' potency and selectivity profiles.  However, high attrition of targeted agents in clin. development suggest that combinations of targeted agents will be most effective in treating solid tumors if the biol. networks that permit cancer cells to subvert monotherapies are identified and retargeted.  Conventional drug-discovery and development strategies are suboptimal for the rational design and development of novel drug combinations.  In this article, we highlight a series of emerging technologies supporting a less reductionist, more agile, drug-discovery and development approach for the rational design, validation, prioritization and clin. development of novel drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKkliYmA82GLVg90H21EOLACvtfcHk0lilt2HuzRL9AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ahtb%252FL&md5=d66f8996ad13dd84ce3667d527bc5516</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.169%26sid%3Dliteratum%253Aachs%26aulast%3DCarragher%26aufirst%3DN.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26aulast%3DCameron%26aufirst%3DD.%26atitle%3DAdvancing%2520drug%2520discovery%2520towards%2520more%2520agile%2520development%2520of%2520targeted%2520combination%2520therapies%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D87%26epage%3D105%26doi%3D10.4155%2Ffmc.11.169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carragher, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unciti-Broceta, A.</span></span> <span> </span><span class="NLM_article-title">eCF309: a potent, selective and cell-permeable mTOR inhibitor</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.1039/C5MD00493D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1039%2FC5MD00493D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVKisbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=471-477&author=C.+Fraserauthor=N.+O.+Carragherauthor=A.+Unciti-Broceta&title=eCF309%3A+a+potent%2C+selective+and+cell-permeable+mTOR+inhibitor&doi=10.1039%2FC5MD00493D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">eCF309: a potent, selective and cell-permeable mTOR inhibitor</span></div><div class="casAuthors">Fraser, Craig; Carragher, Neil O.; Unciti-Broceta, Asier</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">471-477</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Kinase inhibitors capable of blocking the phosphorylation of protein substrates with high selectivity are essential to probe and elucidate the etiol. role of such mols. and their signalling pathways.  By addressing these biochem. questions in disease relevant cell-based and in vivo models, strong pharmacol. evidence can be generated towards validating or disproving a target hypothesis.  Pharmacol. studies can also provide fundamental information to identify appropriate biomarkers and rational drug combination strategies and thereby facilitate clin. translation.  However, due to the high no. of kinases encoded by the human genome (>500) and their highly conserved catalytic domains, the development of such an elite class of inhibitors-a.k.a. high-quality chem. probes-represents a major challenge.  Through a ligand-based inhibitor design, focused library synthesis and phenotypic screening to prioritize compds. with potent cell activity, we recently identified a cell cycle inhibitor with micromolar potency that inhibits mTOR kinase activity.  Following a rapid lead optimization campaign, we report the development of eCF309, an mTOR inhibitor displaying low nanomolar potency both in vitro and in cells and an excellent selectivity profile (S-score (35%) = 0.01 at 10 μM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNXHQGavJnbLVg90H21EOLACvtfcHk0lilt2HuzRL9AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVKisbfN&md5=789b8873b6c84a3a1ffda7396d81dc71</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1039%2FC5MD00493D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00493D%26sid%3Dliteratum%253Aachs%26aulast%3DFraser%26aufirst%3DC.%26aulast%3DCarragher%26aufirst%3DN.%2BO.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26atitle%3DeCF309%253A%2520a%2520potent%252C%2520selective%2520and%2520cell-permeable%2520mTOR%2520inhibitor%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D471%26epage%3D477%26doi%3D10.1039%2FC5MD00493D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carragher, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unciti-Broceta, A.</span></span> <span> </span><span class="NLM_article-title">Rapid discovery and structure–activity relationships of pyrazolopyrimidines that potently suppress breast cancer cell growth via SRC kinase inhibition with exceptional selectivity over ABL kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4697</span>– <span class="NLM_lpage">4710</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00065</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00065" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmsl2rsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4697-4710&author=C.+Fraserauthor=J.+C.+Dawsonauthor=R.+Dowlingauthor=D.+R.+Houstonauthor=J.+T.+Weissauthor=A.+Munroauthor=M.+Muirauthor=L.+Harringtonauthor=S.+P.+Websterauthor=M.+Frameauthor=V.+Bruntonauthor=E.+E.+Pattonauthor=N.+O.+Carragherauthor=A.+Unciti-Broceta&title=Rapid+discovery+and+structure%E2%80%93activity+relationships+of+pyrazolopyrimidines+that+potently+suppress+breast+cancer+cell+growth+via+SRC+kinase+inhibition+with+exceptional+selectivity+over+ABL+kinase&doi=10.1021%2Facs.jmedchem.6b00065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase</span></div><div class="casAuthors">Fraser, Craig; Dawson, John C.; Dowling, Reece; Houston, Douglas R.; Weiss, Jason T.; Munro, Alison F.; Muir, Morwenna; Harrington, Lea; Webster, Scott P.; Frame, Margaret C.; Brunton, Valerie G.; Patton, E. Elizabeth; Carragher, Neil O.; Unciti-Broceta, Asier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4697-4710</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel pyrazolopyrimidines displaying high potency and selectivity toward SRC family kinases have been developed by combining ligand-based design and phenotypic screening in an iterative manner.  Compds. were derived from the promiscuous kinase inhibitor PP1 to search for analogs that could potentially target a broad spectrum of kinases involved in cancer.  Phenotypic screening against MCF7 mammary adenocarcinoma cells generated target-agnostic structure-activity relationships that biased subsequent designs toward breast cancer treatment rather than to a particular target.  This strategy led to the discovery of two potent antiproliferative leads with phenotypically distinct anticancer mode of actions.  Kinase profiling and further optimization resulted in eCF506, the first small mol. with subnanomolar IC50 for SRC that requires 3 orders of magnitude greater concn. to inhibit ABL. eCF506 exhibits excellent water soly., an optimal DMPK profile and oral bioavailability, halts SRC-assocd. neuromast migration in zebrafish embryos without inducing life-threatening heart defects, and inhibits SRC phosphorylation in tumor xenografts in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq55yS4FWveyLVg90H21EOLACvtfcHk0liZCbOcTmqBtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmsl2rsL0%253D&md5=e56206009ccca680432d12db23aa29fd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00065%26sid%3Dliteratum%253Aachs%26aulast%3DFraser%26aufirst%3DC.%26aulast%3DDawson%26aufirst%3DJ.%2BC.%26aulast%3DDowling%26aufirst%3DR.%26aulast%3DHouston%26aufirst%3DD.%2BR.%26aulast%3DWeiss%26aufirst%3DJ.%2BT.%26aulast%3DMunro%26aufirst%3DA.%26aulast%3DMuir%26aufirst%3DM.%26aulast%3DHarrington%26aufirst%3DL.%26aulast%3DWebster%26aufirst%3DS.%2BP.%26aulast%3DFrame%26aufirst%3DM.%26aulast%3DBrunton%26aufirst%3DV.%26aulast%3DPatton%26aufirst%3DE.%2BE.%26aulast%3DCarragher%26aufirst%3DN.%2BO.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26atitle%3DRapid%2520discovery%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520pyrazolopyrimidines%2520that%2520potently%2520suppress%2520breast%2520cancer%2520cell%2520growth%2520via%2520SRC%2520kinase%2520inhibition%2520with%2520exceptional%2520selectivity%2520over%2520ABL%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4697%26epage%3D4710%26doi%3D10.1021%2Facs.jmedchem.6b00065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Myers, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunton, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unciti-Broceta, A.</span></span> <span> </span><span class="NLM_article-title">AXL inhibitors in cancer: A medicinal chemistry perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3593</span>– <span class="NLM_lpage">3608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01273</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01273" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3593-3608&author=S.+H.+Myersauthor=V.+G.+Bruntonauthor=A.+Unciti-Broceta&title=AXL+inhibitors+in+cancer%3A+A+medicinal+chemistry+perspective&doi=10.1021%2Facs.jmedchem.5b01273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Myers, Samuel H.; Brunton, Valerie G.; Unciti-Broceta, Asier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3593-3608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulation of the AXL receptor tyrosine kinase has been assocd. with many types of cancer.  It has not been until recently, however, that targeting AXL has come under the spotlight because of ever accumulating evidence of its strong correlation with poor prognosis and drug resistance.  The entry of the first AXL-branded inhibitor in clin. trials in 2013 marked an important milestone for the clin. validation of AXL as an anticancer target.  Nevertheless, to weigh the current contribution and potential future impact of AXL inhibition in the clinic, it is fundamental to recognize that several kinase inhibitors approved or in clin. development have AXL as either a prominent secondary or even the primary target.  Through this review, the chem. and biol. properties of the main inhibitors targeting AXL (either intentionally or unintentionally) will be discussed, along with the prospects and challenges to translate AXL inhibitors into a bona fide therapeutic option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7-ZTTNRD9LLVg90H21EOLACvtfcHk0liZCbOcTmqBtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbnI&md5=4643d9d9950251a14c3991c306c4cec0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01273%26sid%3Dliteratum%253Aachs%26aulast%3DMyers%26aufirst%3DS.%2BH.%26aulast%3DBrunton%26aufirst%3DV.%2BG.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26atitle%3DAXL%2520inhibitors%2520in%2520cancer%253A%2520A%2520medicinal%2520chemistry%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3593%26epage%3D3608%26doi%3D10.1021%2Facs.jmedchem.5b01273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, L. A.</span></span> <span> </span><span class="NLM_article-title">Giving AXL the axe: targeting AXL in human malignancy</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1038/bjc.2016.428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1038%2Fbjc.2016.428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=28072762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVSruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2017&pages=415-423&author=C.+M.+Gayauthor=K.+Balajiauthor=L.+A.+Byers&title=Giving+AXL+the+axe%3A+targeting+AXL+in+human+malignancy&doi=10.1038%2Fbjc.2016.428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Giving AXL the axe: targeting AXL in human malignancy</span></div><div class="casAuthors">Gay, Carl M.; Balaji, Kavitha; Byers, Lauren Averett</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">415-423</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase AXL, activated by a complex interaction between its ligand growth arrest-specific protein 6 and phosphatidylserine, regulates various vital cellular processes, including proliferation, survival, motility, and immunol. response.  Although not implicated as an oncogenic driver itself, AXL, a member of the TYRO3, AXL, and MERTK family of receptor tyrosine kinases, is overexpressed in several haematol. and solid malignancies, including acute myeloid leukemia, non-small cell lung cancer, gastric and colorectal adenocarcinomas, and breast and prostate cancers.  In the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumor angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response.  As a result, AXL is an attractive candidate not only as a prognostic biomarker in malignancy but also as a target for anticancer therapies.  Several AXL inhibitors are currently in preclin. and clin. development.  This article reviews the structure, regulation, and function of AXL; the role of AXL in the tumor microenvironment; the development of AXL as a therapeutic target; and areas of ongoing and future investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHXM9RJ8TVsLVg90H21EOLACvtfcHk0lg1o_xMWvU0pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVSruw%253D%253D&md5=c24668744fe4b017def75b08bac2a863</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.428%26sid%3Dliteratum%253Aachs%26aulast%3DGay%26aufirst%3DC.%2BM.%26aulast%3DBalaji%26aufirst%3DK.%26aulast%3DByers%26aufirst%3DL.%2BA.%26atitle%3DGiving%2520AXL%2520the%2520axe%253A%2520targeting%2520AXL%2520in%2520human%2520malignancy%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2017%26volume%3D116%26spage%3D415%26epage%3D423%26doi%3D10.1038%2Fbjc.2016.428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundy-Bosse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitman, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearss, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2382</span>– <span class="NLM_lpage">2389</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1038%2Fleu.2015.147" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=2382-2389&author=I.+K.+Parkauthor=B.+Mundy-Bosseauthor=S.+P.+Whitmanauthor=X.+Zhangauthor=S.+L.+Warnerauthor=D.+J.+Bearssauthor=W.+Blumauthor=G.+Marcucciauthor=M.+A.+Caligiuri&title=Receptor+tyrosine+kinase+Axl+is+required+for+resistance+of+leukemic+cells+to+FLT3-targeted+therapy+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2015.147"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.147%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DI.%2BK.%26aulast%3DMundy-Bosse%26aufirst%3DB.%26aulast%3DWhitman%26aufirst%3DS.%2BP.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DBlum%26aufirst%3DW.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520Axl%2520is%2520required%2520for%2520resistance%2520of%2520leukemic%2520cells%2520to%2520FLT3-targeted%2520therapy%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D2382%26epage%3D2389%26doi%3D10.1038%2Fleu.2015.147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schoumacher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burbridge, M.</span></span> <span> </span><span class="NLM_article-title">Key roles of AXL and MER receptor tyrosine kinases in resistance to multiple anticancer therapies</span>. <i>Curr. Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">19</span>, <span class="refDoi"> DOI: 10.1007/s11912-017-0579-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1007%2Fs11912-017-0579-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=28251492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A280%3ADC%252BC1czitVSqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=19&author=M.+Schoumacherauthor=M.+Burbridge&title=Key+roles+of+AXL+and+MER+receptor+tyrosine+kinases+in+resistance+to+multiple+anticancer+therapies&doi=10.1007%2Fs11912-017-0579-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies</span></div><div class="casAuthors">Schoumacher Marie; Burbridge Mike</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A major challenge in anticancer treatment is the pre-existence or emergence of resistance to therapy.  AXL and MER are two members of the TAM (TYRO3-AXL-MER) family of receptor tyrosine kinases, which, when activated, can regulate tumor cell survival, proliferation, migration and invasion, angiogenesis, and tumor-host interactions.  An increasing body of evidence strongly suggests that these receptors play major roles in resistance to targeted therapies and conventional cytotoxic agents.  Multiple resistance mechanisms exist, including the direct and indirect crosstalk of AXL and MER with other receptors and the activation of feedback loops regulating AXL and MER expression and activity.  These mechanisms may be innate, adaptive, or acquired.  A principal role of AXL appears to be in sustaining a mesenchymal phenotype, itself a major mechanism of resistance to diverse anticancer therapies.  Both AXL and MER play a role in the repression of the innate immune response which may also limit response to treatment.  Small molecule and antibody inhibitors of AXL and MER have recently been described, and some of these have already entered clinical trials.  The optimal design of treatment strategies to maximize the clinical benefit of these AXL and MER targeting agents are discussed in relation to the different cancer types and the types of resistance encountered.  One of the major challenges to successful development of these therapies will be the application of robust predictive biomarkers for clear-cut patient stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9gx1KbGDUKHRxY89Cm6SyfW6udTcc2eZLIUMDFatQ8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czitVSqsg%253D%253D&md5=621bbf6ad413ce95a4efb7f247253c8b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs11912-017-0579-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-017-0579-4%26sid%3Dliteratum%253Aachs%26aulast%3DSchoumacher%26aufirst%3DM.%26aulast%3DBurbridge%26aufirst%3DM.%26atitle%3DKey%2520roles%2520of%2520AXL%2520and%2520MER%2520receptor%2520tyrosine%2520kinases%2520in%2520resistance%2520to%2520multiple%2520anticancer%2520therapies%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2017%26volume%3D19%26spage%3D19%26doi%3D10.1007%2Fs11912-017-0579-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grodsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolanos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A.</span></span> <span> </span><span class="NLM_article-title">The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">15705</span>– <span class="NLM_lpage">15716</span>, <span class="refDoi"> DOI: 10.1074/jbc.M116.771485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1074%2Fjbc.M116.771485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=28724631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeqsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=15705-15716&author=K.+S.+Gajiwalaauthor=N.+Grodskyauthor=B.+Bolanosauthor=J.+Fengauthor=R.+Ferreauthor=S.+Timofeevskiauthor=M.+Xuauthor=B.+W.+Murrayauthor=T.+W.+Johnsonauthor=A.+Stewart&title=The+Axl+kinase+domain+in+complex+with+a+macrocyclic+inhibitor+offers+first+structural+insights+into+an+active+TAM+receptor+kinase&doi=10.1074%2Fjbc.M116.771485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase</span></div><div class="casAuthors">Gajiwala, Ketan S.; Grodsky, Neil; Bolanos, Ben; Feng, Junli; Ferre, RoseAnn; Timofeevski, Sergei; Xu, Meirong; Murray, Brion W.; Johnson, Ted W.; Stewart, Al</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">15705-15716</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase family consisting of Tyro3, Axl, and Mer (TAM) is one of the most recently identified receptor tyrosine kinase families.  TAM receptors are up-regulated postnatally and maintained at high levels in adults.  They all play an important role in immunity, but Axl has also been implicated in cancer and therefore is a target in the discovery and development of novel therapeutics.  However, of the three members of the TAM family, the Axl kinase domain is the only one that has so far eluded structure detn.  To this end, using differential scanning fluorimetry and hydrogen-deuterium exchange mass spectrometry, we show here that a lower stability and greater dynamic nature of the Axl kinase domain may account for its poor crystallizability.  We present the first structural characterization of the Axl kinase domain in complex with a small-mol. macrocyclic inhibitor.  The Axl crystal structure revealed two distinct conformational states of the enzyme, providing a first glimpse of what an active TAM receptor kinase may look like and suggesting a potential role for the juxtamembrane region in enzyme activity.  We noted that the ATP/inhibitor-binding sites of the TAM members closely resemble each other, posing a challenge for the design of a selective inhibitor.  We propose that the differences in the conformational dynamics among the TAM family members could potentially be exploited to achieve inhibitor selectivity for targeted receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVvxI1tF-DxrVg90H21EOLACvtfcHk0lg1o_xMWvU0pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeqsLjJ&md5=d334fffff7c7b11f1daab8db9b255a80</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M116.771485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M116.771485%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFerre%26aufirst%3DR.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DStewart%26aufirst%3DA.%26atitle%3DThe%2520Axl%2520kinase%2520domain%2520in%2520complex%2520with%2520a%2520macrocyclic%2520inhibitor%2520offers%2520first%2520structural%2520insights%2520into%2520an%2520active%2520TAM%2520receptor%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26spage%3D15705%26epage%3D15716%26doi%3D10.1074%2Fjbc.M116.771485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRyckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Deusen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sather, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korboukh, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzen, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of small molecule mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1021/ml200239k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200239k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=129-134&author=J.+Liuauthor=C.+Yangauthor=C.+Simpsonauthor=D.+DeRyckereauthor=A.+Van+Deusenauthor=M.+J.+Mileyauthor=D.+Kireevauthor=J.+Norris-Drouinauthor=S.+Satherauthor=D.+Hunterauthor=V.+K.+Korboukhauthor=H.+S.+Patelauthor=W.+P.+Janzenauthor=M.+Machiusauthor=G.+L.+Johnsonauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=Discovery+of+small+molecule+mer+kinase+inhibitors+for+the+treatment+of+pediatric+acute+lymphoblastic+leukemia&doi=10.1021%2Fml200239k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fml200239k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200239k%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DSimpson%26aufirst%3DC.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DVan%2BDeusen%26aufirst%3DA.%26aulast%3DMiley%26aufirst%3DM.%2BJ.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DKorboukh%26aufirst%3DV.%2BK.%26aulast%3DPatel%26aufirst%3DH.%2BS.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DMachius%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520small%2520molecule%2520mer%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520pediatric%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D129%26epage%3D134%26doi%3D10.1021%2Fml200239k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finerty, P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler-Cole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span> <span> </span><span class="NLM_article-title">Structural insights into the inhibited states of the Mer receptor tyrosine kinase</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.jsb.2008.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1016%2Fj.jsb.2008.10.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2009&pages=88-96&author=X.+Huangauthor=P.+Finertyauthor=J.+R.+Walkerauthor=C.+Butler-Coleauthor=M.+Vedadiauthor=M.+Schapiraauthor=S.+Parkerauthor=B.+Turkauthor=D.+A.+Thompsonauthor=S.+Dhe-Paganon&title=Structural+insights+into+the+inhibited+states+of+the+Mer+receptor+tyrosine+kinase&doi=10.1016%2Fj.jsb.2008.10.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2008.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2008.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DFinerty%26aufirst%3DP.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DButler-Cole%26aufirst%3DC.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DS.%26aulast%3DTurk%26aufirst%3DB.%26aulast%3DThompson%26aufirst%3DD.%2BA.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26atitle%3DStructural%2520insights%2520into%2520the%2520inhibited%2520states%2520of%2520the%2520Mer%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2009%26volume%3D165%26spage%3D88%26epage%3D96%26doi%3D10.1016%2Fj.jsb.2008.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, C.</span></span> <span> </span><span class="NLM_article-title">First Axl inhibitor enters clinical trials</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1038/nbt0913-775a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1038%2Fnbt0913-775a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=775-776&author=C.+Sheridan&title=First+Axl+inhibitor+enters+clinical+trials&doi=10.1038%2Fnbt0913-775a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnbt0913-775a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt0913-775a%26sid%3Dliteratum%253Aachs%26aulast%3DSheridan%26aufirst%3DC.%26atitle%3DFirst%2520Axl%2520inhibitor%2520enters%2520clinical%2520trials%26jtitle%3DNat.%2520Biotechnol.%26date%3D2013%26volume%3D31%26spage%3D775%26epage%3D776%26doi%3D10.1038%2Fnbt0913-775a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quentmeier, H.</span></span> <span> </span><span class="NLM_article-title">Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.3109/10428199909093728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.3109%2F10428199909093728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10194124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlsFSlu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1999&pages=83-91&author=H.+G.+Drexlerauthor=C.+Meyerauthor=H.+Quentmeier&title=Effects+of+FLT3+ligand+on+proliferation+and+survival+of+myeloid+leukemia+cells&doi=10.3109%2F10428199909093728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells</span></div><div class="casAuthors">Drexler, Hans G.; Meyer, Corinna; Quentmeier, Hilmar</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">83-91</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Harwood Academic Publishers</span>)
        </div><div class="casAbstract">A review, with 44 refs.  FLT3 ligand (FL) acting through its tyrosine kinase receptor FLT3 has pleiotropic and potent effects on hematopoietic cells.  The well-described involvement of this ligand-receptor pair in physiol. hematopoiesis raised the question whether FL and FLT3 also play a role in the pathobiol. of leukemia.  Following the early discovery of high receptor expression by myeloid leukemia cells, several investigators have focused their attention on these cells, both primary acute myeloid leukemia (AML) cells and continuous human myeloid leukemia cell lines.  Regardless of the morphol. FAB subtype, the vast majority of AML cases were FLT3-pos. both at the mRNA and protein level; among the myeloid cell lines, predominantly the monocytic and myelocytic cell lines were FLT3-pos. whereas the erythrocytic and megakaryocytic cell lines were FLT3-neg.  Virtually all cell lines studied expressed FL transcripts; the finding that some cell lines displayed both ligand and receptor indicates the possibility of autocrine, intracrine or paracrine stimulatory loops.  In vitro growth assays showed that FL caused a proliferative response in a high percentage of AML cases.  Only constitutively growth factor-dependent myelocytic cell lines increased their proliferation upon incubation with FL whereas all growth factor-independent cell lines were refractory to FL stimulation.  Combinations of FL with various cytokines (e.g. G-CSF, GM-CSF, IL-3, M-CSF, PIXY-321, SCF) had synergistic or additive mitogenic effects.  Finally, FL had significant anti-apoptotic, survival-promoting effects on primary AML cells and myeloid cell lines under serum-free culture conditions.  On the strength of the above findings, it can be concluded that the FL-FLT3 signaling system may play a certain, albeit probably not causal role in the development of human leukemias.  Dissection of the exact mol. pathways that lead to proliferation and/or anti-apoptosis of myeloid leukemia cells as well as the detailed elucidation of the possible contribution of the FL-FLT3 genes to leukemogenesis remain future challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGommyHevCac5rVg90H21EOLACvtfcHk0liIjYQQ__TO7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlsFSlu74%253D&md5=c7c8f95373f6b2d4509d5e3816608f01</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3109%2F10428199909093728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10428199909093728%26sid%3Dliteratum%253Aachs%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26aulast%3DMeyer%26aufirst%3DC.%26aulast%3DQuentmeier%26aufirst%3DH.%26atitle%3DEffects%2520of%2520FLT3%2520ligand%2520on%2520proliferation%2520and%2520survival%2520of%2520myeloid%2520leukemia%2520cells%26jtitle%3DLeuk.%2520Lymphoma%26date%3D1999%26volume%3D33%26spage%3D83%26epage%3D91%26doi%3D10.3109%2F10428199909093728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vardiman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunning, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowitz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porwit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Beau, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom-Lindberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span> <span> </span><span class="NLM_article-title">The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-03-209262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1182%2Fblood-2009-03-209262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=19357394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1eit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=937-51&author=J.+W.+Vardimanauthor=J.+Thieleauthor=D.+A.+Arberauthor=R.+D.+Brunningauthor=M.+J.+Borowitzauthor=A.+Porwitauthor=N.+L.+Harrisauthor=M.+M.+Le+Beauauthor=E.+Hellstrom-Lindbergauthor=A.+Tefferiauthor=C.+D.+Bloomfield&title=The+2008+revision+of+the+World+Health+Organization+%28WHO%29+classification+of+myeloid+neoplasms+and+acute+leukemia%3A+rationale+and+important+changes&doi=10.1182%2Fblood-2009-03-209262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes</span></div><div class="casAuthors">Vardiman, James W.; Thiele, Juergen; Arber, Daniel A.; Brunning, Richard D.; Borowitz, Michael J.; Porwit, Anna; Harris, Nancy Lee; Le Beau, Michelle M.; Hellstrom-Lindberg, Eva; Tefferi, Ayalew; Bloomfield, Clara D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">937-951</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Recently the World Health Organization (WHO), in collaboration with the European Assocn. for Haematopathol. and the Society for Hematopathol., published a revised and updated edition of the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues.  The 4th edition of the WHO classification incorporates new information that has emerged from scientific and clin. studies in the interval since the publication of the 3rd edition in 2001, and includes new criteria for the recognition of some previously described neoplasms as well as clarification and refinement of the defining criteria for others.  It also adds entities-some defined principally by genetic features-that have only recently been characterized.  In this paper, the classification of myeloid neoplasms and acute leukemia is highlighted with the aim of familiarizing hematologists, clin. scientists, and hematopathologists not only with the major changes in the classification but also with the rationale for those changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAsL8uAlluK7Vg90H21EOLACvtfcHk0li4KjNCrYK_ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1eit70%253D&md5=c458e03fa4a3dc3584a593ac72b3b002</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-03-209262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-03-209262%26sid%3Dliteratum%253Aachs%26aulast%3DVardiman%26aufirst%3DJ.%2BW.%26aulast%3DThiele%26aufirst%3DJ.%26aulast%3DArber%26aufirst%3DD.%2BA.%26aulast%3DBrunning%26aufirst%3DR.%2BD.%26aulast%3DBorowitz%26aufirst%3DM.%2BJ.%26aulast%3DPorwit%26aufirst%3DA.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DLe%2BBeau%26aufirst%3DM.%2BM.%26aulast%3DHellstrom-Lindberg%26aufirst%3DE.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26atitle%3DThe%25202008%2520revision%2520of%2520the%2520World%2520Health%2520Organization%2520%2528WHO%2529%2520classification%2520of%2520myeloid%2520neoplasms%2520and%2520acute%2520leukemia%253A%2520rationale%2520and%2520important%2520changes%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D937%26epage%3D51%26doi%3D10.1182%2Fblood-2009-03-209262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer</span>. <i>J. Int. Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">656</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1177/147323000803600406</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1177%2F147323000803600406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=18652760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A280%3ADC%252BD1cvnsVeruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=656-664&author=Q.+Zengauthor=Y.+Chengauthor=Q.+Zhuauthor=Z.+Yuauthor=X.+Wuauthor=K.+Huangauthor=M.+Zhouauthor=S.+Hanauthor=Q.+Zhang&title=The+relationship+between+overexpression+of+glial+cell-derived+neurotrophic+factor+and+its+RET+receptor+with+progression+and+prognosis+of+human+pancreatic+cancer&doi=10.1177%2F147323000803600406"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer</span></div><div class="casAuthors">Zeng Q; Cheng Y; Zhu Q; Yu Z; Wu X; Huang K; Zhou M; Han S; Zhang Q</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of international medical research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">656-64</span>
        ISSN:<span class="NLM_cas:issn">0300-0605</span>.
    </div><div class="casAbstract">We used immunohistochemical staining to assess protein over-expression of glial cell-derived neurotrophic factor (GDNF) and its RET receptor tyrosine kinase in patients with pancreatic cancer and benign pancreatic neoplasm, and assessed correlations with clinicopathological features and prognosis.  Surgically resected pancreatic cancer patients (40/58, 68.9%) showed positive GDNF immunostaining, a significantly higher frequency than in patients with benign pancreatic tumour (3/11, 27.3%).  Intrapancreatic neural invasion by cancer cells was significantly related to over-expression of GDNF.  Strongly positive expression of GDNF was significantly more frequent than lesser grades of expression in patients with severe back pain before and 12 months after surgery.  Expression of RET was significantly related to lymphatic invasion, survival rate after tumour resection and degree of tumour cell differentiation.  We conclude that GDNF may be important in pancreatic cancer proliferation and metastasis, especially in patients with perineural invasion.  Strongly positive expression of GDNF may be an indication for early intensified radiotherapy.  RET expression in pancreatic cancer tissues may be a useful prognostic marker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRb1rJwh9SOLNTiMd2aNQVUfW6udTcc2eZd9UQLJwi1MLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvnsVeruw%253D%253D&md5=41c80625fb4530e36b43aafc7bdd44ac</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1177%2F147323000803600406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F147323000803600406%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DThe%2520relationship%2520between%2520overexpression%2520of%2520glial%2520cell-derived%2520neurotrophic%2520factor%2520and%2520its%2520RET%2520receptor%2520with%2520progression%2520and%2520prognosis%2520of%2520human%2520pancreatic%2520cancer%26jtitle%3DJ.%2520Int.%2520Med.%2520Res.%26date%3D2008%26volume%3D36%26spage%3D656%26epage%3D664%26doi%3D10.1177%2F147323000803600406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pancholi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plaza-Menacho, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacke, C. M.</span></span> <span> </span><span class="NLM_article-title">GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">3783</span>– <span class="NLM_lpage">3795</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-4265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1158%2F0008-5472.CAN-12-4265" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=3783-3795&author=A.+Morandiauthor=L.+A.+Martinauthor=Q.+Gaoauthor=S.+Pancholiauthor=A.+Mackayauthor=D.+Robertsonauthor=M.+Zvelebilauthor=M.+Dowsettauthor=I.+Plaza-Menachoauthor=C.+M.+Isacke&title=GDNF-RET+signaling+in+ER-positive+breast+cancers+is+a+key+determinant+of+response+and+resistance+to+aromatase+inhibitors&doi=10.1158%2F0008-5472.CAN-12-4265"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-4265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-4265%26sid%3Dliteratum%253Aachs%26aulast%3DMorandi%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DL.%2BA.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DPancholi%26aufirst%3DS.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DD.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DDowsett%26aufirst%3DM.%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DIsacke%26aufirst%3DC.%2BM.%26atitle%3DGDNF-RET%2520signaling%2520in%2520ER-positive%2520breast%2520cancers%2520is%2520a%2520key%2520determinant%2520of%2520response%2520and%2520resistance%2520to%2520aromatase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D3783%26epage%3D3795%26doi%3D10.1158%2F0008-5472.CAN-12-4265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gattei, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldinucci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Iuliis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzocco, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagonel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, A.</span></span> <span> </span><span class="NLM_article-title">Differential expression of the RET gene in human acute myeloid leukemia</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1007/s002770050444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1007%2Fs002770050444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=9858145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADyaK1cXnsVOhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1998&pages=207-210&author=V.+Gatteiauthor=M.+Deganauthor=D.+Aldinucciauthor=A.+De+Iuliisauthor=F.+M.+Rossiauthor=F.+T.+Mazzoccoauthor=M.+Rupoloauthor=V.+Zagonelauthor=A.+Pinto&title=Differential+expression+of+the+RET+gene+in+human+acute+myeloid+leukemia&doi=10.1007%2Fs002770050444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Differential expression of the RET gene in human acute myeloid leukemia</span></div><div class="casAuthors">Gattei, V.; Degan, M.; Aldinucci, D.; Iuliis, A. De; Rossi, F. Maria; Mazzocco, F. Tassan; Rupolo, M.; Zagonel, V.; Pinto, A.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Hematology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">207-210</span>CODEN:
                <span class="NLM_cas:coden">ANHEE8</span>;
        ISSN:<span class="NLM_cas:issn">0939-5555</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">The RET proto-oncogene product is a receptor tyrosine kinase representing the signal-transducing mol. of a multi-subunit membrane receptor complex for at least two different types of transforming growth factor (TGF)-β-related neurotrophic factors.  We have previously shown that RET gene expression in acute myeloid leukemia (AML) occurs more frequently in AMLs displaying either a monocytic (FAB M4/M5) or intermediate-mature myeloid phenotype (FAB M2/M3) than in leukemias reflecting an earlier stage of myeloid differentiation (FAB M0/M1).  To further verify the assocn. between RET expression and the relative maturation stage of AML cells, we have performed a quant. estn. of relative abundances of RET transcripts among various FAB subtypes of AMLs.  By analyzing 13 AML samples and normal hematopoietic cells through a competitive-quant. RT-PCR approach, we were able to show that the relative levels of RET-specific mRNAs continuously increase with blast cell maturation in human AML, i.e., the amts. of RET gene-specific transcripts differ among RET-expressing AMLs, being higher in the more differentiated FAB phenotypes.  In addn., we provide evidence that the relative amts. of RET transcripts increase upon in vitro and in vivo differentiation of leukemic promyelocytes from FAB M3 AML patients, becoming overall comparable to those found in normal granulocytes.  These results indicate that RET expression in human AMLs is maturation-assocd., probably mirroring the developmental regulation of this gene during differentiation of normal hematopoietic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou4hJ4RRKPWLVg90H21EOLACvtfcHk0li4KjNCrYK_ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnsVOhtL8%253D&md5=d536906a9dc1d8a3135601e4ecfcd04c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs002770050444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002770050444%26sid%3Dliteratum%253Aachs%26aulast%3DGattei%26aufirst%3DV.%26aulast%3DDegan%26aufirst%3DM.%26aulast%3DAldinucci%26aufirst%3DD.%26aulast%3DDe%2BIuliis%26aufirst%3DA.%26aulast%3DRossi%26aufirst%3DF.%2BM.%26aulast%3DMazzocco%26aufirst%3DF.%2BT.%26aulast%3DRupolo%26aufirst%3DM.%26aulast%3DZagonel%26aufirst%3DV.%26aulast%3DPinto%26aufirst%3DA.%26atitle%3DDifferential%2520expression%2520of%2520the%2520RET%2520gene%2520in%2520human%2520acute%2520myeloid%2520leukemia%26jtitle%3DAnn.%2520Hematol.%26date%3D1998%26volume%3D77%26spage%3D207%26epage%3D210%26doi%3D10.1007%2Fs002770050444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Batalla, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loges, S.</span></span> <span> </span><span class="NLM_article-title">Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1586/17474086.2015.997704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1586%2F17474086.2015.997704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=25578023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFems7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=135-138&author=M.+Janningauthor=I.+Ben-Batallaauthor=S.+Loges&title=Axl+inhibition%3A+a+potential+road+to+a+novel+acute+myeloid+leukemia+therapy%3F&doi=10.1586%2F17474086.2015.997704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?</span></div><div class="casAuthors">Janning, Melanie; Ben-Batalla, Isabel; Loges, Sonja</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-138</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Novel treatment options in acute myeloid leukemia (AML) are urgently needed; treatment has not changed significantly over the past decades and survival is still dismal, esp. in elderly patients.  Axl, a member of the Tyro3, Axl, Mer (TAM) receptor family, mediates proliferation and survival of AML cells and is upregulated upon cytostatic treatment.  In addn., AML cells induce expression of the Axl ligand growth arrest-specific gene 6 (Gas6) in bone marrow stroma cells, which further amplifies their growth and therapy resistance.  Interruption of Axl signaling by pharmacol. approaches, including the small mol. Axl inhibitor BGB324, decreased disease burden and prolonged survival of AML mice.  The Gas6-Axl pathway has translational relevance because Axl is expressed by approx. 50% of AML patients and Axl-targeting approaches can block growth of primary human AML cells.  Thus, Axl represents a potential novel target in AML and BGB324 is now in clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkMKGtwTcHcrVg90H21EOLACvtfcHk0lgS5eBTbMKDTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFems7Y%253D&md5=493a441cabca1f0f5aca7614f1283786</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1586%2F17474086.2015.997704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F17474086.2015.997704%26sid%3Dliteratum%253Aachs%26aulast%3DJanning%26aufirst%3DM.%26aulast%3DBen-Batalla%26aufirst%3DI.%26aulast%3DLoges%26aufirst%3DS.%26atitle%3DAxl%2520inhibition%253A%2520a%2520potential%2520road%2520to%2520a%2520novel%2520acute%2520myeloid%2520leukemia%2520therapy%253F%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2015%26volume%3D8%26spage%3D135%26epage%3D138%26doi%3D10.1586%2F17474086.2015.997704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span> </span><span class="NLM_article-title">NCT02488408</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2015</span>; <a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a> (accessed
Oct 19, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NCT02488408.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2015%3B+www.clinicaltrials.gov+%28accessed%0AOct+19%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNCT02488408%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cetkovic-Cvrlje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uckun, F. M.</span></span> <span> </span><span class="NLM_article-title">Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases</span>. <i>Arch. Immunol. Ther. Exp.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">82</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=15179321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslGqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=69-82&author=M.+Cetkovic-Cvrljeauthor=F.+M.+Uckun&title=Targeting+Janus+kinase+3+in+the+treatment+of+leukemia+and+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases</span></div><div class="casAuthors">Cetkovic-Cvrlje, Marina; Uckun, Fatih M.</div><div class="citationInfo"><span class="NLM_cas:title">Archivum Immunologiae et Therapiae Experimentalis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-82</span>CODEN:
                <span class="NLM_cas:coden">AITEAT</span>;
        ISSN:<span class="NLM_cas:issn">0004-069X</span>.
    
            (<span class="NLM_cas:orgname">Ossolineum Publishing House</span>)
        </div><div class="casAbstract">A review.  Janus tyrosine kinases (JAKs) are cytoplasmic protein tyrosine kinases that play a crucial role in the initial steps of cytokine signaling.  JAK3, a member of JAK kinase family of four (JAK1, JAK2, JAK3 and TYK2), is abundantly expressed in lymphoid cells.  JAK3 has been found to initiate signaling of interleukin (IL)-2, IL-4, IL-7, IL-9, IL-13 and IL-15.  Indispensable role of JAK3 in lymphocyte development and function has been revealed recently.  Because of the involvement of JAK3 in T cell activation and proliferation, and the documented genetic evidence for the role of JAK3 in autoimmune or transplant-induced inflammatory disorders, the selective targeting of JAK3 in T cells may potentially be clin. beneficial in T cell-derived pathol. disorders.  In this review we discuss inhibitors of JAK3 as a new class of immunomodulatory agents with immunosuppressive, anti-inflammatory, anti-allergic, and anti-leukemic properties.  Preclin. data from multiple exptl. model systems of autoimmune diabetes, allergy, solid organ transplantation, pancreatic islet transplantation and bone marrow transplantation are discussed in the context of the clin. need for new immunomodulatory agents with such properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1mQfft89qdrVg90H21EOLACvtfcHk0lgS5eBTbMKDTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslGqurY%253D&md5=0cde7ccfd4752712d48f7ee587ee7975</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCetkovic-Cvrlje%26aufirst%3DM.%26aulast%3DUckun%26aufirst%3DF.%2BM.%26atitle%3DTargeting%2520Janus%2520kinase%25203%2520in%2520the%2520treatment%2520of%2520leukemia%2520and%2520inflammatory%2520diseases%26jtitle%3DArch.%2520Immunol.%2520Ther.%2520Exp.%26date%3D2004%26volume%3D52%26spage%3D69%26epage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polzer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krupka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg-Thurley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzeler, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dörfel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salih, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nößner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeremias, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiddemann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subklewe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greif, P. A.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1038%2Fleu.2017.257" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=313-322&author=K.+Reiterauthor=H.+Polzerauthor=C.+Krupkaauthor=A.+Maiserauthor=B.+Vickauthor=M.+Rothenberg-Thurleyauthor=K.+H.+Metzelerauthor=D.+D%C3%B6rfelauthor=H.+R.+Salihauthor=G.+Jungauthor=E.+N%C3%B6%C3%9Fnerauthor=I.+Jeremiasauthor=W.+Hiddemannauthor=H.+Leonhardtauthor=K.+Spiekermannauthor=M.+Subkleweauthor=P.+A.+Greif&title=Tyrosine+kinase+inhibition+increases+the+cell+surface+localization+of+FLT3-ITD+and+enhances+FLT3-directed+immunotherapy+of+acute+myeloid+leukemia&doi=10.1038%2Fleu.2017.257"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.257%26sid%3Dliteratum%253Aachs%26aulast%3DReiter%26aufirst%3DK.%26aulast%3DPolzer%26aufirst%3DH.%26aulast%3DKrupka%26aufirst%3DC.%26aulast%3DMaiser%26aufirst%3DA.%26aulast%3DVick%26aufirst%3DB.%26aulast%3DRothenberg-Thurley%26aufirst%3DM.%26aulast%3DMetzeler%26aufirst%3DK.%2BH.%26aulast%3DD%25C3%25B6rfel%26aufirst%3DD.%26aulast%3DSalih%26aufirst%3DH.%2BR.%26aulast%3DJung%26aufirst%3DG.%26aulast%3DN%25C3%25B6%25C3%259Fner%26aufirst%3DE.%26aulast%3DJeremias%26aufirst%3DI.%26aulast%3DHiddemann%26aufirst%3DW.%26aulast%3DLeonhardt%26aufirst%3DH.%26aulast%3DSpiekermann%26aufirst%3DK.%26aulast%3DSubklewe%26aufirst%3DM.%26aulast%3DGreif%26aufirst%3DP.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibition%2520increases%2520the%2520cell%2520surface%2520localization%2520of%2520FLT3-ITD%2520and%2520enhances%2520FLT3-directed%2520immunotherapy%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D313%26epage%3D322%26doi%3D10.1038%2Fleu.2017.257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 13 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ming-Shu Wang, Hong-Chuang Xu, Yi Gong, Ren-Yu Qu, Lin-Sheng Zhuo, <span class="NLM_string-name hlFld-ContribAuthor">Wei Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Arylation of 2,7-Naphthyridin-1(2H)-one with Diaryliodonium Salts and Discovery of a New Selective MET/AXL Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2020,</strong> <em>22 </em>
                                    (9)
                                     , 457-467. <a href="https://doi.org/10.1021/acscombsci.0c00074" title="DOI URL">https://doi.org/10.1021/acscombsci.0c00074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.0c00074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.0c00074%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DEfficient%252BArylation%252Bof%252B2%25252C7-Naphthyridin-1%2525282H%252529-one%252Bwith%252BDiaryliodonium%252BSalts%252Band%252BDiscovery%252Bof%252Ba%252BNew%252BSelective%252BMET%25252FAXL%252BKinase%252BInhibitor%26aulast%3DWang%26aufirst%3DMing-Shu%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03052020%26date%3D22062020%26date%3D10072020%26date%3D26062020%26volume%3D22%26issue%3D9%26spage%3D457%26epage%3D467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Olga Cruz-López, Carolin Temps, Beatrice Longo, Samuel H. Myers, Francisco Franco-Montalban, <span class="NLM_string-name hlFld-ContribAuthor">Asier Unciti-Broceta</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Characterization of a Click-Assembled 18-Atom Macrocycle That Displays Selective AXL Kinase Inhibitory Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (25)
                                     , 21620-21626. <a href="https://doi.org/10.1021/acsomega.9b03525" title="DOI URL">https://doi.org/10.1021/acsomega.9b03525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b03525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b03525%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DSynthesis%252Band%252BCharacterization%252Bof%252Ba%252BClick-Assembled%252B18-Atom%252BMacrocycle%252BThat%252BDisplays%252BSelective%252BAXL%252BKinase%252BInhibitory%252BActivity%26aulast%3DCruz-L%25C3%25B3pez%26aufirst%3DOlga%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22102019%26date%3D14112019%26date%3D03122019%26volume%3D4%26issue%3D25%26spage%3D21620%26epage%3D21626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eddie L  Myers</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5–6 Systems: Other Four Heteroatoms 2:2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00056-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00056-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00056-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00056-1%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5%2525E2%252580%2525936%252BSystems%25253A%252BOther%252BFour%252BHeteroatoms%252B2%25253A2%26aulast%3DMyers%26aufirst%3DEddie%2BL%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2021%26volume%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rossella  Di Stasi</span>, <span class="hlFld-ContribAuthor ">Lucia  De Rosa</span>, <span class="hlFld-ContribAuthor ">Luca D.  D’Andrea</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic aspects of the Axl/Gas6 molecular system. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (12)
                                     , 2130-2148. <a href="https://doi.org/10.1016/j.drudis.2020.09.022" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.09.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.09.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.09.022%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DTherapeutic%252Baspects%252Bof%252Bthe%252BAxl%25252FGas6%252Bmolecular%252Bsystem%26aulast%3DDi%2BStasi%26aufirst%3DRossella%26date%3D2020%26volume%3D25%26issue%3D12%26spage%3D2130%26epage%3D2148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel J.  Baillache</span>, <span class="hlFld-ContribAuthor ">Asier  Unciti-Broceta</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-
              d
              ]pyrimidine scaffold. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1112-1135. <a href="https://doi.org/10.1039/D0MD00227E" title="DOI URL">https://doi.org/10.1039/D0MD00227E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00227E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00227E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bdevelopments%252Bin%252Banticancer%252Bkinase%252Binhibitors%252Bbased%252Bon%252Bthe%252Bpyrazolo%25255B3%25252C4-%252Bd%252B%25255Dpyrimidine%252Bscaffold%26aulast%3DBaillache%26aufirst%3DDaniel%2BJ.%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D10%26spage%3D1112%26epage%3D1135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lexian  Tong</span>, <span class="hlFld-ContribAuthor ">Xuemei  Li</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in FLT3 inhibitors for acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 961-981. <a href="https://doi.org/10.4155/fmc-2019-0365" title="DOI URL">https://doi.org/10.4155/fmc-2019-0365</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0365%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252BFLT3%252Binhibitors%252Bfor%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DTong%26aufirst%3DLexian%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D961%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Teresa  Valero</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Baillache</span>, <span class="hlFld-ContribAuthor ">Craig  Fraser</span>, <span class="hlFld-ContribAuthor ">Samuel H.  Myers</span>, <span class="hlFld-ContribAuthor ">Asier  Unciti-Broceta</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrazolopyrimide library screening in glioma cells discovers highly potent antiproliferative leads that target the PI3K/mTOR pathway. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (1)
                                     , 115215. <a href="https://doi.org/10.1016/j.bmc.2019.115215" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.115215</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.115215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.115215%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DPyrazolopyrimide%252Blibrary%252Bscreening%252Bin%252Bglioma%252Bcells%252Bdiscovers%252Bhighly%252Bpotent%252Bantiproliferative%252Bleads%252Bthat%252Btarget%252Bthe%252BPI3K%25252FmTOR%252Bpathway%26aulast%3DValero%26aufirst%3DTeresa%26date%3D2020%26volume%3D28%26issue%3D1%26spage%3D115215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Congjun  Xu</span>, <span class="hlFld-ContribAuthor ">Yufei  Han</span>, <span class="hlFld-ContribAuthor ">Sicong  Xu</span>, <span class="hlFld-ContribAuthor ">Ruxin  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Yue</span>, <span class="hlFld-ContribAuthor ">Yu  Tian</span>, <span class="hlFld-ContribAuthor ">Xiaofan  Li</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>186 </em>, 111867. <a href="https://doi.org/10.1016/j.ejmech.2019.111867" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111867</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111867%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnew%252BAxl%252Bkinase%252Binhibitors%252Bcontaining%252B1%25252C3%25252C4-oxadiazole%252Bacetamide%252Bmoiety%252Bas%252Bnovel%252Blinker%26aulast%3DXu%26aufirst%3DCongjun%26date%3D2020%26volume%3D186%26spage%3D111867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiaoling  Xu</span>, <span class="hlFld-ContribAuthor ">Baozhu  Dai</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Li</span>, <span class="hlFld-ContribAuthor ">Le  Xu</span>, <span class="hlFld-ContribAuthor ">Di  Yang</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Yunlei  Hou</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (19)
                                     , 126630. <a href="https://doi.org/10.1016/j.bmcl.2019.126630" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126630</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126630%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252B4-%252528%2525286%25252C7-dimethoxyquinoline-4-yl%252529oxy%252529aniline%252Bderivatives%252Bas%252BFLT3%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DXu%26aufirst%3DQiaoling%26date%3D2019%26volume%3D29%26issue%3D19%26spage%3D126630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhi-Gang  Sun</span>, <span class="hlFld-ContribAuthor ">Jian-Hua  Liu</span>, <span class="hlFld-ContribAuthor ">Jin-Mai  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Qian</span>. </span><span class="cited-content_cbyCitation_article-title">Research Progress of Axl Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (15)
                                     , 1338-1349. <a href="https://doi.org/10.2174/1568026619666190620155613" title="DOI URL">https://doi.org/10.2174/1568026619666190620155613</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190620155613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190620155613%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DResearch%252BProgress%252Bof%252BAxl%252BInhibitors%26aulast%3DSun%26aufirst%3DZhi-Gang%26date%3D2019%26volume%3D19%26issue%3D15%26spage%3D1338%26epage%3D1349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Tan</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Donglin  Gao</span>, <span class="hlFld-ContribAuthor ">Shingpan  Chan</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Zheng-Chao  Tu</span>, <span class="hlFld-ContribAuthor ">Zhi-Min  Zhang</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Quinolone antibiotic derivatives as new selective Axl kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>166 </em>, 318-327. <a href="https://doi.org/10.1016/j.ejmech.2019.01.065" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.01.065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.01.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.01.065%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DQuinolone%252Bantibiotic%252Bderivatives%252Bas%252Bnew%252Bselective%252BAxl%252Bkinase%252Binhibitors%26aulast%3DTan%26aufirst%3DLi%26date%3D2019%26volume%3D166%26spage%3D318%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhao-Shan  Niu</span>, <span class="hlFld-ContribAuthor ">Xiao-Jun  Niu</span>, <span class="hlFld-ContribAuthor ">Wen-Hong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Role of the receptor tyrosine kinase Axl in hepatocellular carcinoma and its clinical relevance. </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (6)
                                     , 653-662. <a href="https://doi.org/10.2217/fon-2018-0528" title="DOI URL">https://doi.org/10.2217/fon-2018-0528</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon-2018-0528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon-2018-0528%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DRole%252Bof%252Bthe%252Breceptor%252Btyrosine%252Bkinase%252BAxl%252Bin%252Bhepatocellular%252Bcarcinoma%252Band%252Bits%252Bclinical%252Brelevance%26aulast%3DNiu%26aufirst%3DZhao-Shan%26date%3D2019%26volume%3D15%26issue%3D6%26spage%3D653%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">K.  Thirumurugan</span>, <span class="hlFld-ContribAuthor ">Sivalingam  Lakshmanan</span>, <span class="hlFld-ContribAuthor ">Dharman  Govindaraj</span>, <span class="hlFld-ContribAuthor ">D. Sam  Daniel Prabu</span>, <span class="hlFld-ContribAuthor ">N.  Ramalakshmi</span>, <span class="hlFld-ContribAuthor ">S.  Arul Antony</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and anti-inflammatory activity of pyrimidine scaffold benzamide derivatives as epidermal growth factor receptor tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2018,</strong> <em>1171 </em>, 541-550. <a href="https://doi.org/10.1016/j.molstruc.2018.06.003" title="DOI URL">https://doi.org/10.1016/j.molstruc.2018.06.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2018.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2018.06.003%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Banti-inflammatory%252Bactivity%252Bof%252Bpyrimidine%252Bscaffold%252Bbenzamide%252Bderivatives%252Bas%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DThirumurugan%26aufirst%3DK.%26date%3D2018%26volume%3D1171%26spage%3D541%26epage%3D550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Medicinal chemistry campaign based on the cocrystal structure of <b>52</b> and MER (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2G15">2G15</a><a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a>) performed by Wang and co-workers<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> for the discovery of MER inhibitor UNC569 and the 6-methylaminopyrazolo[3,4-<i>d</i>]pyrimidine scaffold explored in this work.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Four-Step Synthetic Route for the Preparation of Compounds <b>7a</b>–<b>j</b> from Commercially Available 6-Chloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine, <b>3</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. EC<sub>50</sub> values of <b>7a</b>–<b>j</b> and the positive control foretinib against AXL<sup>–</sup> (red) and AXL<sup>+</sup> (blue) cells. Cell viability assay: PrestoBlue reagent at day 5. Error bars: ±SD from <i>n</i> = 2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route for the Preparation of Triazole-Containing Compounds <b>10a</b>–<b>g</b> from Intermediate <b>5</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. EC<sub>50</sub> values of <b>10a</b>–<b>g</b> and reference hit <b>7f</b> against AXL<sup>–</sup> (red) and AXL<sup>+</sup> (blue) cells. Cell viability assay: PrestoBlue reagent at day 5. Error bars: ±SD from <i>n</i> = 2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structure, molecular weight (MW), and cLogP of derivatives <b>12a</b>–<b>f</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. EC<sub>50</sub> values of <b>12a</b>–<b>f</b> and reference hit <b>10a</b> against AXL<sup>–</sup> (red) and AXL<sup>+</sup> (blue) cells. Cell viability assay: PrestoBlue reagent at day 5. Error bars: ±SD from <i>n</i> = 2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structure, MW, and cLogP of derivatives <b>13a</b>–<b>d</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. EC<sub>50</sub> values of <b>13a</b>–<b>d</b> and BGB324 against MV4-11 and MOLM-13 cells. Cell viability assay: PrestoBlue reagent at day 5. Error bars: ±SD from <i>n</i> = 2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/medium/jm-2017-016058_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Map of the human kinome screened for <b>13a</b> at 1 μM. Green circles denote <65% inhibition. Red circles denote >65% inhibition (>98% for the largest one).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01605/20180313/images/large/jm-2017-016058_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01605&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53717" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53717" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 25 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avorn, J.</span></span> <span> </span><span class="NLM_article-title">The $2.6 Billion pill — methodologic and policy considerations</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1877</span>– <span class="NLM_lpage">1879</span>, <span class="refDoi"> DOI: 10.1056/NEJMp1500848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1056%2FNEJMp1500848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=25970049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlehs73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1877-1879&author=J.+Avorn&title=The+%242.6+Billion+pill+%E2%80%94+methodologic+and+policy+considerations&doi=10.1056%2FNEJMp1500848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The $2.6 billion pill - methodologic and policy considerations</span></div><div class="casAuthors">Avorn, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1877-1879</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwRcSjishmd7Vg90H21EOLACvtfcHk0lhSzMJWkgDlrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlehs73J&md5=6a4f7872393d76f1a9748f4be5968565</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMp1500848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp1500848%26sid%3Dliteratum%253Aachs%26aulast%3DAvorn%26aufirst%3DJ.%26atitle%3DThe%2520%25242.6%2520Billion%2520pill%2520%25E2%2580%2594%2520methodologic%2520and%2520policy%2520considerations%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1877%26epage%3D1879%26doi%3D10.1056%2FNEJMp1500848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DiMasi, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, R. W.</span></span> <span> </span><span class="NLM_article-title">Innovation in the pharmaceutical industry: New estimates of R&D costs</span>. <i>J. Health. Econ.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.jhealeco.2016.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1016%2Fj.jhealeco.2016.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=26928437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A280%3ADC%252BC28jls1egsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2016&pages=20-33&author=J.+A.+DiMasiauthor=H.+G.+Grabowskiauthor=R.+W.+Hansen&title=Innovation+in+the+pharmaceutical+industry%3A+New+estimates+of+R%26D+costs&doi=10.1016%2Fj.jhealeco.2016.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Innovation in the pharmaceutical industry: New estimates of R&D costs</span></div><div class="casAuthors">DiMasi Joseph A; Grabowski Henry G; Hansen Ronald W</div><div class="citationInfo"><span class="NLM_cas:title">Journal of health economics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The research and development costs of 106 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms.  These data were used to estimate the average pre-tax cost of new drug and biologics development.  The costs of compounds abandoned during testing were linked to the costs of compounds that obtained marketing approval.  The estimated average out-of-pocket cost per approved new compound is $1395 million (2013 dollars).  Capitalizing out-of-pocket costs to the point of marketing approval at a real discount rate of 10.5% yields a total pre-approval cost estimate of $2558 million (2013 dollars).  When compared to the results of the previous study in this series, total capitalized costs were shown to have increased at an annual rate of 8.5% above general price inflation.  Adding an estimate of post-approval R&D costs increases the cost estimate to $2870 million (2013 dollars).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ64KxQIdSPM8K3uFsUIZtkfW6udTcc2eY73g6YLrUgCLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jls1egsw%253D%253D&md5=a78649853406ddbfe54abb0052ca964b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.jhealeco.2016.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhealeco.2016.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DDiMasi%26aufirst%3DJ.%2BA.%26aulast%3DGrabowski%26aufirst%3DH.%2BG.%26aulast%3DHansen%26aufirst%3DR.%2BW.%26atitle%3DInnovation%2520in%2520the%2520pharmaceutical%2520industry%253A%2520New%2520estimates%2520of%2520R%2526D%2520costs%26jtitle%3DJ.%2520Health.%2520Econ.%26date%3D2016%26volume%3D47%26spage%3D20%26epage%3D33%26doi%3D10.1016%2Fj.jhealeco.2016.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kola, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landis, J.</span></span> <span> </span><span class="NLM_article-title">Can the pharmaceutical industry reduce attrition rates?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">711</span>– <span class="NLM_lpage">716</span>, <span class="refDoi"> DOI: 10.1038/nrd1470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1038%2Fnrd1470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=15286737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=711-716&author=I.+Kolaauthor=J.+Landis&title=Can+the+pharmaceutical+industry+reduce+attrition+rates%3F&doi=10.1038%2Fnrd1470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Opinion: Can the pharmaceutical industry reduce attrition rates?</span></div><div class="casAuthors">Kola, Ismail; Landis, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">711-716</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry faces considerable challenges, both politically and fiscally.  Politically, governments around the world are trying to contain costs and, as health care budgets constitute a very significant part of governmental spending, these costs are the subject of intense scrutiny.  In the United States, drug costs are also the subject of intense political discourse.  This article deals with the fiscal pressures that face the industry from the perspective of R&D.  What impinges on productivity How can we improve current reduced R&D productivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruAlrpFPFmiLVg90H21EOLACvtfcHk0lhSzMJWkgDlrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVOhtLs%253D&md5=f9025c13a1506f607aaf68415570ed01</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd1470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1470%26sid%3Dliteratum%253Aachs%26aulast%3DKola%26aufirst%3DI.%26aulast%3DLandis%26aufirst%3DJ.%26atitle%3DCan%2520the%2520pharmaceutical%2520industry%2520reduce%2520attrition%2520rates%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D711%26epage%3D716%26doi%3D10.1038%2Fnrd1470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlik, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moxham, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomandl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sall, D. J.</span></span> <span> </span><span class="NLM_article-title">Modern phenotypic drug discovery is a viable, neoclassic pharma strategy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4527</span>– <span class="NLM_lpage">4538</span>, <span class="refDoi"> DOI: 10.1021/jm201649s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201649s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1OitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4527-4538&author=J.+A.+Leeauthor=M.+T.+Uhlikauthor=C.+M.+Moxhamauthor=D.+Tomandlauthor=D.+J.+Sall&title=Modern+phenotypic+drug+discovery+is+a+viable%2C+neoclassic+pharma+strategy&doi=10.1021%2Fjm201649s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy</span></div><div class="casAuthors">Lee, Jonathan A.; Uhlik, Mark T.; Moxham, Christopher M.; Tomandl, Dirk; Sall, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4527-4538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pharmaceutical industry (Pharma) is currently facing unprecedented challenges.  In addn. to strategic patent expirations, the rate of drug launches has been essentially const. for 60 years with overall productivity falling since the 1970s.  Similarly, the appearance of novel targets to FDA approved drugs, a measure of industry innovation, has not dramatically improved since the 1980s.  Although Pharma productivity is a multifaceted problem, detailed analyses of comprehensive, industry-wide data indicate that late stage clin. failures are a major contributor that has been attributed to poor target validation (TV) and the lack of predictive biomarkers that translate to the clinic.  In the spirit of "reinventing innovation" Pharma needs to introspectively identify areas for improvement.  This communication considers how choices in drug screening strategies may relate to target validation issues and influence the probability of identifying novel medicines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8CcODiYYNgLVg90H21EOLACvtfcHk0lhSzMJWkgDlrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1OitLs%253D&md5=1937641b632e348d7566c016ca4cf51d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm201649s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201649s%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BA.%26aulast%3DUhlik%26aufirst%3DM.%2BT.%26aulast%3DMoxham%26aufirst%3DC.%2BM.%26aulast%3DTomandl%26aufirst%3DD.%26aulast%3DSall%26aufirst%3DD.%2BJ.%26atitle%3DModern%2520phenotypic%2520drug%2520discovery%2520is%2520a%2520viable%252C%2520neoclassic%2520pharma%2520strategy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4527%26epage%3D4538%26doi%3D10.1021%2Fjm201649s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Targeting the cancer kinome through polypharmacology</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1038/nrc2787</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1038%2Fnrc2787" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=20094047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=130-137&author=Z.+Knightauthor=H.+Linauthor=K.+M.+Shokat&title=Targeting+the+cancer+kinome+through+polypharmacology&doi=10.1038%2Fnrc2787"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cancer kinome through polypharmacology</span></div><div class="casAuthors">Knight, Zachary A.; Lin, Henry; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-137</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Kinase inhibitors are the largest class of new cancer drugs.  However, it is already apparent that most tumors can escape from the inhibition of any single kinase.  If it is necessary to inhibit multiple kinases, how do we choose which ones.  In this Opinion article, we discuss some of the strategies that are currently being used to identify new therapeutic combinations of kinase targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkDv2FeeH58rVg90H21EOLACvtfcHk0ljjUbHTLG8dJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXps1Clug%253D%253D&md5=9aaa314e54b43889e147a9f11ac77072</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrc2787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2787%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520the%2520cancer%2520kinome%2520through%2520polypharmacology%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D130%26epage%3D137%26doi%3D10.1038%2Fnrc2787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carragher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unciti-Broceta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, D.</span></span> <span> </span><span class="NLM_article-title">Advancing drug discovery towards more agile development of targeted combination therapies</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.4155%2Ffmc.11.169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=22168166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ahtb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=87-105&author=N.+Carragherauthor=A.+Unciti-Brocetaauthor=D.+Cameron&title=Advancing+drug+discovery+towards+more+agile+development+of+targeted+combination+therapies&doi=10.4155%2Ffmc.11.169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing cancer drug discovery towards more agile development of targeted combination therapies</span></div><div class="casAuthors">Carragher, Neil O.; Unciti-Broceta, Asier; Cameron, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-105</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Current drug-discovery strategies are typically target-centric'' and are based upon high-throughput screening of large chem. libraries against nominated targets and a selection of lead compds. with optimized on-target'' potency and selectivity profiles.  However, high attrition of targeted agents in clin. development suggest that combinations of targeted agents will be most effective in treating solid tumors if the biol. networks that permit cancer cells to subvert monotherapies are identified and retargeted.  Conventional drug-discovery and development strategies are suboptimal for the rational design and development of novel drug combinations.  In this article, we highlight a series of emerging technologies supporting a less reductionist, more agile, drug-discovery and development approach for the rational design, validation, prioritization and clin. development of novel drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKkliYmA82GLVg90H21EOLACvtfcHk0ljjUbHTLG8dJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ahtb%252FL&md5=d66f8996ad13dd84ce3667d527bc5516</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.169%26sid%3Dliteratum%253Aachs%26aulast%3DCarragher%26aufirst%3DN.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26aulast%3DCameron%26aufirst%3DD.%26atitle%3DAdvancing%2520drug%2520discovery%2520towards%2520more%2520agile%2520development%2520of%2520targeted%2520combination%2520therapies%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D87%26epage%3D105%26doi%3D10.4155%2Ffmc.11.169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carragher, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unciti-Broceta, A.</span></span> <span> </span><span class="NLM_article-title">eCF309: a potent, selective and cell-permeable mTOR inhibitor</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">471</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.1039/C5MD00493D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1039%2FC5MD00493D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVKisbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=471-477&author=C.+Fraserauthor=N.+O.+Carragherauthor=A.+Unciti-Broceta&title=eCF309%3A+a+potent%2C+selective+and+cell-permeable+mTOR+inhibitor&doi=10.1039%2FC5MD00493D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">eCF309: a potent, selective and cell-permeable mTOR inhibitor</span></div><div class="casAuthors">Fraser, Craig; Carragher, Neil O.; Unciti-Broceta, Asier</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">471-477</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Kinase inhibitors capable of blocking the phosphorylation of protein substrates with high selectivity are essential to probe and elucidate the etiol. role of such mols. and their signalling pathways.  By addressing these biochem. questions in disease relevant cell-based and in vivo models, strong pharmacol. evidence can be generated towards validating or disproving a target hypothesis.  Pharmacol. studies can also provide fundamental information to identify appropriate biomarkers and rational drug combination strategies and thereby facilitate clin. translation.  However, due to the high no. of kinases encoded by the human genome (>500) and their highly conserved catalytic domains, the development of such an elite class of inhibitors-a.k.a. high-quality chem. probes-represents a major challenge.  Through a ligand-based inhibitor design, focused library synthesis and phenotypic screening to prioritize compds. with potent cell activity, we recently identified a cell cycle inhibitor with micromolar potency that inhibits mTOR kinase activity.  Following a rapid lead optimization campaign, we report the development of eCF309, an mTOR inhibitor displaying low nanomolar potency both in vitro and in cells and an excellent selectivity profile (S-score (35%) = 0.01 at 10 μM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNXHQGavJnbLVg90H21EOLACvtfcHk0lhwcWLeVSNNMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVKisbfN&md5=789b8873b6c84a3a1ffda7396d81dc71</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1039%2FC5MD00493D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00493D%26sid%3Dliteratum%253Aachs%26aulast%3DFraser%26aufirst%3DC.%26aulast%3DCarragher%26aufirst%3DN.%2BO.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26atitle%3DeCF309%253A%2520a%2520potent%252C%2520selective%2520and%2520cell-permeable%2520mTOR%2520inhibitor%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26spage%3D471%26epage%3D477%26doi%3D10.1039%2FC5MD00493D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frame, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patton, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carragher, N. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unciti-Broceta, A.</span></span> <span> </span><span class="NLM_article-title">Rapid discovery and structure–activity relationships of pyrazolopyrimidines that potently suppress breast cancer cell growth via SRC kinase inhibition with exceptional selectivity over ABL kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4697</span>– <span class="NLM_lpage">4710</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00065</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00065" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmsl2rsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4697-4710&author=C.+Fraserauthor=J.+C.+Dawsonauthor=R.+Dowlingauthor=D.+R.+Houstonauthor=J.+T.+Weissauthor=A.+Munroauthor=M.+Muirauthor=L.+Harringtonauthor=S.+P.+Websterauthor=M.+Frameauthor=V.+Bruntonauthor=E.+E.+Pattonauthor=N.+O.+Carragherauthor=A.+Unciti-Broceta&title=Rapid+discovery+and+structure%E2%80%93activity+relationships+of+pyrazolopyrimidines+that+potently+suppress+breast+cancer+cell+growth+via+SRC+kinase+inhibition+with+exceptional+selectivity+over+ABL+kinase&doi=10.1021%2Facs.jmedchem.6b00065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase</span></div><div class="casAuthors">Fraser, Craig; Dawson, John C.; Dowling, Reece; Houston, Douglas R.; Weiss, Jason T.; Munro, Alison F.; Muir, Morwenna; Harrington, Lea; Webster, Scott P.; Frame, Margaret C.; Brunton, Valerie G.; Patton, E. Elizabeth; Carragher, Neil O.; Unciti-Broceta, Asier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4697-4710</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel pyrazolopyrimidines displaying high potency and selectivity toward SRC family kinases have been developed by combining ligand-based design and phenotypic screening in an iterative manner.  Compds. were derived from the promiscuous kinase inhibitor PP1 to search for analogs that could potentially target a broad spectrum of kinases involved in cancer.  Phenotypic screening against MCF7 mammary adenocarcinoma cells generated target-agnostic structure-activity relationships that biased subsequent designs toward breast cancer treatment rather than to a particular target.  This strategy led to the discovery of two potent antiproliferative leads with phenotypically distinct anticancer mode of actions.  Kinase profiling and further optimization resulted in eCF506, the first small mol. with subnanomolar IC50 for SRC that requires 3 orders of magnitude greater concn. to inhibit ABL. eCF506 exhibits excellent water soly., an optimal DMPK profile and oral bioavailability, halts SRC-assocd. neuromast migration in zebrafish embryos without inducing life-threatening heart defects, and inhibits SRC phosphorylation in tumor xenografts in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq55yS4FWveyLVg90H21EOLACvtfcHk0lhwcWLeVSNNMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmsl2rsL0%253D&md5=e56206009ccca680432d12db23aa29fd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00065%26sid%3Dliteratum%253Aachs%26aulast%3DFraser%26aufirst%3DC.%26aulast%3DDawson%26aufirst%3DJ.%2BC.%26aulast%3DDowling%26aufirst%3DR.%26aulast%3DHouston%26aufirst%3DD.%2BR.%26aulast%3DWeiss%26aufirst%3DJ.%2BT.%26aulast%3DMunro%26aufirst%3DA.%26aulast%3DMuir%26aufirst%3DM.%26aulast%3DHarrington%26aufirst%3DL.%26aulast%3DWebster%26aufirst%3DS.%2BP.%26aulast%3DFrame%26aufirst%3DM.%26aulast%3DBrunton%26aufirst%3DV.%26aulast%3DPatton%26aufirst%3DE.%2BE.%26aulast%3DCarragher%26aufirst%3DN.%2BO.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26atitle%3DRapid%2520discovery%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520pyrazolopyrimidines%2520that%2520potently%2520suppress%2520breast%2520cancer%2520cell%2520growth%2520via%2520SRC%2520kinase%2520inhibition%2520with%2520exceptional%2520selectivity%2520over%2520ABL%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4697%26epage%3D4710%26doi%3D10.1021%2Facs.jmedchem.6b00065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Myers, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunton, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unciti-Broceta, A.</span></span> <span> </span><span class="NLM_article-title">AXL inhibitors in cancer: A medicinal chemistry perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3593</span>– <span class="NLM_lpage">3608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01273</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01273" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3593-3608&author=S.+H.+Myersauthor=V.+G.+Bruntonauthor=A.+Unciti-Broceta&title=AXL+inhibitors+in+cancer%3A+A+medicinal+chemistry+perspective&doi=10.1021%2Facs.jmedchem.5b01273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Myers, Samuel H.; Brunton, Valerie G.; Unciti-Broceta, Asier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3593-3608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulation of the AXL receptor tyrosine kinase has been assocd. with many types of cancer.  It has not been until recently, however, that targeting AXL has come under the spotlight because of ever accumulating evidence of its strong correlation with poor prognosis and drug resistance.  The entry of the first AXL-branded inhibitor in clin. trials in 2013 marked an important milestone for the clin. validation of AXL as an anticancer target.  Nevertheless, to weigh the current contribution and potential future impact of AXL inhibition in the clinic, it is fundamental to recognize that several kinase inhibitors approved or in clin. development have AXL as either a prominent secondary or even the primary target.  Through this review, the chem. and biol. properties of the main inhibitors targeting AXL (either intentionally or unintentionally) will be discussed, along with the prospects and challenges to translate AXL inhibitors into a bona fide therapeutic option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7-ZTTNRD9LLVg90H21EOLACvtfcHk0lhwcWLeVSNNMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWnsbnI&md5=4643d9d9950251a14c3991c306c4cec0</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01273%26sid%3Dliteratum%253Aachs%26aulast%3DMyers%26aufirst%3DS.%2BH.%26aulast%3DBrunton%26aufirst%3DV.%2BG.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26atitle%3DAXL%2520inhibitors%2520in%2520cancer%253A%2520A%2520medicinal%2520chemistry%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3593%26epage%3D3608%26doi%3D10.1021%2Facs.jmedchem.5b01273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gay, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, L. A.</span></span> <span> </span><span class="NLM_article-title">Giving AXL the axe: targeting AXL in human malignancy</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1038/bjc.2016.428</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1038%2Fbjc.2016.428" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=28072762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvVSruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2017&pages=415-423&author=C.+M.+Gayauthor=K.+Balajiauthor=L.+A.+Byers&title=Giving+AXL+the+axe%3A+targeting+AXL+in+human+malignancy&doi=10.1038%2Fbjc.2016.428"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Giving AXL the axe: targeting AXL in human malignancy</span></div><div class="casAuthors">Gay, Carl M.; Balaji, Kavitha; Byers, Lauren Averett</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">415-423</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase AXL, activated by a complex interaction between its ligand growth arrest-specific protein 6 and phosphatidylserine, regulates various vital cellular processes, including proliferation, survival, motility, and immunol. response.  Although not implicated as an oncogenic driver itself, AXL, a member of the TYRO3, AXL, and MERTK family of receptor tyrosine kinases, is overexpressed in several haematol. and solid malignancies, including acute myeloid leukemia, non-small cell lung cancer, gastric and colorectal adenocarcinomas, and breast and prostate cancers.  In the context of malignancy, evidence suggests that AXL overexpression drives wide-ranging processes, including epithelial to mesenchymal transition, tumor angiogenesis, resistance to chemotherapeutic and targeted agents, and decreased antitumor immune response.  As a result, AXL is an attractive candidate not only as a prognostic biomarker in malignancy but also as a target for anticancer therapies.  Several AXL inhibitors are currently in preclin. and clin. development.  This article reviews the structure, regulation, and function of AXL; the role of AXL in the tumor microenvironment; the development of AXL as a therapeutic target; and areas of ongoing and future investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHXM9RJ8TVsLVg90H21EOLACvtfcHk0lggpupDLXyTnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvVSruw%253D%253D&md5=c24668744fe4b017def75b08bac2a863</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2016.428&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2016.428%26sid%3Dliteratum%253Aachs%26aulast%3DGay%26aufirst%3DC.%2BM.%26aulast%3DBalaji%26aufirst%3DK.%26aulast%3DByers%26aufirst%3DL.%2BA.%26atitle%3DGiving%2520AXL%2520the%2520axe%253A%2520targeting%2520AXL%2520in%2520human%2520malignancy%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2017%26volume%3D116%26spage%3D415%26epage%3D423%26doi%3D10.1038%2Fbjc.2016.428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundy-Bosse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitman, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearss, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caligiuri, M. A.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2382</span>– <span class="NLM_lpage">2389</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1038%2Fleu.2015.147" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=2382-2389&author=I.+K.+Parkauthor=B.+Mundy-Bosseauthor=S.+P.+Whitmanauthor=X.+Zhangauthor=S.+L.+Warnerauthor=D.+J.+Bearssauthor=W.+Blumauthor=G.+Marcucciauthor=M.+A.+Caligiuri&title=Receptor+tyrosine+kinase+Axl+is+required+for+resistance+of+leukemic+cells+to+FLT3-targeted+therapy+in+acute+myeloid+leukemia&doi=10.1038%2Fleu.2015.147"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.147%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DI.%2BK.%26aulast%3DMundy-Bosse%26aufirst%3DB.%26aulast%3DWhitman%26aufirst%3DS.%2BP.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DBlum%26aufirst%3DW.%26aulast%3DMarcucci%26aufirst%3DG.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520Axl%2520is%2520required%2520for%2520resistance%2520of%2520leukemic%2520cells%2520to%2520FLT3-targeted%2520therapy%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D2382%26epage%3D2389%26doi%3D10.1038%2Fleu.2015.147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schoumacher, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burbridge, M.</span></span> <span> </span><span class="NLM_article-title">Key roles of AXL and MER receptor tyrosine kinases in resistance to multiple anticancer therapies</span>. <i>Curr. Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">19</span>, <span class="refDoi"> DOI: 10.1007/s11912-017-0579-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1007%2Fs11912-017-0579-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=28251492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A280%3ADC%252BC1czitVSqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=19&author=M.+Schoumacherauthor=M.+Burbridge&title=Key+roles+of+AXL+and+MER+receptor+tyrosine+kinases+in+resistance+to+multiple+anticancer+therapies&doi=10.1007%2Fs11912-017-0579-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies</span></div><div class="casAuthors">Schoumacher Marie; Burbridge Mike</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A major challenge in anticancer treatment is the pre-existence or emergence of resistance to therapy.  AXL and MER are two members of the TAM (TYRO3-AXL-MER) family of receptor tyrosine kinases, which, when activated, can regulate tumor cell survival, proliferation, migration and invasion, angiogenesis, and tumor-host interactions.  An increasing body of evidence strongly suggests that these receptors play major roles in resistance to targeted therapies and conventional cytotoxic agents.  Multiple resistance mechanisms exist, including the direct and indirect crosstalk of AXL and MER with other receptors and the activation of feedback loops regulating AXL and MER expression and activity.  These mechanisms may be innate, adaptive, or acquired.  A principal role of AXL appears to be in sustaining a mesenchymal phenotype, itself a major mechanism of resistance to diverse anticancer therapies.  Both AXL and MER play a role in the repression of the innate immune response which may also limit response to treatment.  Small molecule and antibody inhibitors of AXL and MER have recently been described, and some of these have already entered clinical trials.  The optimal design of treatment strategies to maximize the clinical benefit of these AXL and MER targeting agents are discussed in relation to the different cancer types and the types of resistance encountered.  One of the major challenges to successful development of these therapies will be the application of robust predictive biomarkers for clear-cut patient stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS9gx1KbGDUKHRxY89Cm6SyfW6udTcc2eYLgWTaM2YyTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czitVSqsg%253D%253D&md5=621bbf6ad413ce95a4efb7f247253c8b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs11912-017-0579-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-017-0579-4%26sid%3Dliteratum%253Aachs%26aulast%3DSchoumacher%26aufirst%3DM.%26aulast%3DBurbridge%26aufirst%3DM.%26atitle%3DKey%2520roles%2520of%2520AXL%2520and%2520MER%2520receptor%2520tyrosine%2520kinases%2520in%2520resistance%2520to%2520multiple%2520anticancer%2520therapies%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2017%26volume%3D19%26spage%3D19%26doi%3D10.1007%2Fs11912-017-0579-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grodsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolanos, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A.</span></span> <span> </span><span class="NLM_article-title">The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">15705</span>– <span class="NLM_lpage">15716</span>, <span class="refDoi"> DOI: 10.1074/jbc.M116.771485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1074%2Fjbc.M116.771485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=28724631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeqsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=15705-15716&author=K.+S.+Gajiwalaauthor=N.+Grodskyauthor=B.+Bolanosauthor=J.+Fengauthor=R.+Ferreauthor=S.+Timofeevskiauthor=M.+Xuauthor=B.+W.+Murrayauthor=T.+W.+Johnsonauthor=A.+Stewart&title=The+Axl+kinase+domain+in+complex+with+a+macrocyclic+inhibitor+offers+first+structural+insights+into+an+active+TAM+receptor+kinase&doi=10.1074%2Fjbc.M116.771485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase</span></div><div class="casAuthors">Gajiwala, Ketan S.; Grodsky, Neil; Bolanos, Ben; Feng, Junli; Ferre, RoseAnn; Timofeevski, Sergei; Xu, Meirong; Murray, Brion W.; Johnson, Ted W.; Stewart, Al</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">15705-15716</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase family consisting of Tyro3, Axl, and Mer (TAM) is one of the most recently identified receptor tyrosine kinase families.  TAM receptors are up-regulated postnatally and maintained at high levels in adults.  They all play an important role in immunity, but Axl has also been implicated in cancer and therefore is a target in the discovery and development of novel therapeutics.  However, of the three members of the TAM family, the Axl kinase domain is the only one that has so far eluded structure detn.  To this end, using differential scanning fluorimetry and hydrogen-deuterium exchange mass spectrometry, we show here that a lower stability and greater dynamic nature of the Axl kinase domain may account for its poor crystallizability.  We present the first structural characterization of the Axl kinase domain in complex with a small-mol. macrocyclic inhibitor.  The Axl crystal structure revealed two distinct conformational states of the enzyme, providing a first glimpse of what an active TAM receptor kinase may look like and suggesting a potential role for the juxtamembrane region in enzyme activity.  We noted that the ATP/inhibitor-binding sites of the TAM members closely resemble each other, posing a challenge for the design of a selective inhibitor.  We propose that the differences in the conformational dynamics among the TAM family members could potentially be exploited to achieve inhibitor selectivity for targeted receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVvxI1tF-DxrVg90H21EOLACvtfcHk0lggpupDLXyTnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeqsLjJ&md5=d334fffff7c7b11f1daab8db9b255a80</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M116.771485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M116.771485%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFerre%26aufirst%3DR.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DJohnson%26aufirst%3DT.%2BW.%26aulast%3DStewart%26aufirst%3DA.%26atitle%3DThe%2520Axl%2520kinase%2520domain%2520in%2520complex%2520with%2520a%2520macrocyclic%2520inhibitor%2520offers%2520first%2520structural%2520insights%2520into%2520an%2520active%2520TAM%2520receptor%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26spage%3D15705%26epage%3D15716%26doi%3D10.1074%2Fjbc.M116.771485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRyckere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Deusen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kireev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris-Drouin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sather, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korboukh, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janzen, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of small molecule mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1021/ml200239k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200239k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=129-134&author=J.+Liuauthor=C.+Yangauthor=C.+Simpsonauthor=D.+DeRyckereauthor=A.+Van+Deusenauthor=M.+J.+Mileyauthor=D.+Kireevauthor=J.+Norris-Drouinauthor=S.+Satherauthor=D.+Hunterauthor=V.+K.+Korboukhauthor=H.+S.+Patelauthor=W.+P.+Janzenauthor=M.+Machiusauthor=G.+L.+Johnsonauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=Discovery+of+small+molecule+mer+kinase+inhibitors+for+the+treatment+of+pediatric+acute+lymphoblastic+leukemia&doi=10.1021%2Fml200239k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fml200239k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200239k%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DSimpson%26aufirst%3DC.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DVan%2BDeusen%26aufirst%3DA.%26aulast%3DMiley%26aufirst%3DM.%2BJ.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DKorboukh%26aufirst%3DV.%2BK.%26aulast%3DPatel%26aufirst%3DH.%2BS.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DMachius%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520small%2520molecule%2520mer%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520pediatric%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D129%26epage%3D134%26doi%3D10.1021%2Fml200239k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finerty, P.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler-Cole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span> <span> </span><span class="NLM_article-title">Structural insights into the inhibited states of the Mer receptor tyrosine kinase</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.jsb.2008.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1016%2Fj.jsb.2008.10.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2009&pages=88-96&author=X.+Huangauthor=P.+Finertyauthor=J.+R.+Walkerauthor=C.+Butler-Coleauthor=M.+Vedadiauthor=M.+Schapiraauthor=S.+Parkerauthor=B.+Turkauthor=D.+A.+Thompsonauthor=S.+Dhe-Paganon&title=Structural+insights+into+the+inhibited+states+of+the+Mer+receptor+tyrosine+kinase&doi=10.1016%2Fj.jsb.2008.10.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2008.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2008.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DFinerty%26aufirst%3DP.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DButler-Cole%26aufirst%3DC.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DS.%26aulast%3DTurk%26aufirst%3DB.%26aulast%3DThompson%26aufirst%3DD.%2BA.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26atitle%3DStructural%2520insights%2520into%2520the%2520inhibited%2520states%2520of%2520the%2520Mer%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2009%26volume%3D165%26spage%3D88%26epage%3D96%26doi%3D10.1016%2Fj.jsb.2008.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, C.</span></span> <span> </span><span class="NLM_article-title">First Axl inhibitor enters clinical trials</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">775</span>– <span class="NLM_lpage">776</span>, <span class="refDoi"> DOI: 10.1038/nbt0913-775a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1038%2Fnbt0913-775a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=775-776&author=C.+Sheridan&title=First+Axl+inhibitor+enters+clinical+trials&doi=10.1038%2Fnbt0913-775a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnbt0913-775a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt0913-775a%26sid%3Dliteratum%253Aachs%26aulast%3DSheridan%26aufirst%3DC.%26atitle%3DFirst%2520Axl%2520inhibitor%2520enters%2520clinical%2520trials%26jtitle%3DNat.%2520Biotechnol.%26date%3D2013%26volume%3D31%26spage%3D775%26epage%3D776%26doi%3D10.1038%2Fnbt0913-775a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quentmeier, H.</span></span> <span> </span><span class="NLM_article-title">Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.3109/10428199909093728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.3109%2F10428199909093728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10194124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlsFSlu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1999&pages=83-91&author=H.+G.+Drexlerauthor=C.+Meyerauthor=H.+Quentmeier&title=Effects+of+FLT3+ligand+on+proliferation+and+survival+of+myeloid+leukemia+cells&doi=10.3109%2F10428199909093728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells</span></div><div class="casAuthors">Drexler, Hans G.; Meyer, Corinna; Quentmeier, Hilmar</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">83-91</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1042-8194</span>.
    
            (<span class="NLM_cas:orgname">Harwood Academic Publishers</span>)
        </div><div class="casAbstract">A review, with 44 refs.  FLT3 ligand (FL) acting through its tyrosine kinase receptor FLT3 has pleiotropic and potent effects on hematopoietic cells.  The well-described involvement of this ligand-receptor pair in physiol. hematopoiesis raised the question whether FL and FLT3 also play a role in the pathobiol. of leukemia.  Following the early discovery of high receptor expression by myeloid leukemia cells, several investigators have focused their attention on these cells, both primary acute myeloid leukemia (AML) cells and continuous human myeloid leukemia cell lines.  Regardless of the morphol. FAB subtype, the vast majority of AML cases were FLT3-pos. both at the mRNA and protein level; among the myeloid cell lines, predominantly the monocytic and myelocytic cell lines were FLT3-pos. whereas the erythrocytic and megakaryocytic cell lines were FLT3-neg.  Virtually all cell lines studied expressed FL transcripts; the finding that some cell lines displayed both ligand and receptor indicates the possibility of autocrine, intracrine or paracrine stimulatory loops.  In vitro growth assays showed that FL caused a proliferative response in a high percentage of AML cases.  Only constitutively growth factor-dependent myelocytic cell lines increased their proliferation upon incubation with FL whereas all growth factor-independent cell lines were refractory to FL stimulation.  Combinations of FL with various cytokines (e.g. G-CSF, GM-CSF, IL-3, M-CSF, PIXY-321, SCF) had synergistic or additive mitogenic effects.  Finally, FL had significant anti-apoptotic, survival-promoting effects on primary AML cells and myeloid cell lines under serum-free culture conditions.  On the strength of the above findings, it can be concluded that the FL-FLT3 signaling system may play a certain, albeit probably not causal role in the development of human leukemias.  Dissection of the exact mol. pathways that lead to proliferation and/or anti-apoptosis of myeloid leukemia cells as well as the detailed elucidation of the possible contribution of the FL-FLT3 genes to leukemogenesis remain future challenges.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGommyHevCac5rVg90H21EOLACvtfcHk0lhFnMfKc3X7WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlsFSlu74%253D&md5=c7c8f95373f6b2d4509d5e3816608f01</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3109%2F10428199909093728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10428199909093728%26sid%3Dliteratum%253Aachs%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26aulast%3DMeyer%26aufirst%3DC.%26aulast%3DQuentmeier%26aufirst%3DH.%26atitle%3DEffects%2520of%2520FLT3%2520ligand%2520on%2520proliferation%2520and%2520survival%2520of%2520myeloid%2520leukemia%2520cells%26jtitle%3DLeuk.%2520Lymphoma%26date%3D1999%26volume%3D33%26spage%3D83%26epage%3D91%26doi%3D10.3109%2F10428199909093728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vardiman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunning, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowitz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porwit, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Beau, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellstrom-Lindberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloomfield, C. D.</span></span> <span> </span><span class="NLM_article-title">The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">937</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-03-209262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1182%2Fblood-2009-03-209262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=19357394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BD1MXps1eit70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=937-51&author=J.+W.+Vardimanauthor=J.+Thieleauthor=D.+A.+Arberauthor=R.+D.+Brunningauthor=M.+J.+Borowitzauthor=A.+Porwitauthor=N.+L.+Harrisauthor=M.+M.+Le+Beauauthor=E.+Hellstrom-Lindbergauthor=A.+Tefferiauthor=C.+D.+Bloomfield&title=The+2008+revision+of+the+World+Health+Organization+%28WHO%29+classification+of+myeloid+neoplasms+and+acute+leukemia%3A+rationale+and+important+changes&doi=10.1182%2Fblood-2009-03-209262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes</span></div><div class="casAuthors">Vardiman, James W.; Thiele, Juergen; Arber, Daniel A.; Brunning, Richard D.; Borowitz, Michael J.; Porwit, Anna; Harris, Nancy Lee; Le Beau, Michelle M.; Hellstrom-Lindberg, Eva; Tefferi, Ayalew; Bloomfield, Clara D.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">937-951</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Recently the World Health Organization (WHO), in collaboration with the European Assocn. for Haematopathol. and the Society for Hematopathol., published a revised and updated edition of the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues.  The 4th edition of the WHO classification incorporates new information that has emerged from scientific and clin. studies in the interval since the publication of the 3rd edition in 2001, and includes new criteria for the recognition of some previously described neoplasms as well as clarification and refinement of the defining criteria for others.  It also adds entities-some defined principally by genetic features-that have only recently been characterized.  In this paper, the classification of myeloid neoplasms and acute leukemia is highlighted with the aim of familiarizing hematologists, clin. scientists, and hematopathologists not only with the major changes in the classification but also with the rationale for those changes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAsL8uAlluK7Vg90H21EOLACvtfcHk0lgueDsSzRayhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXps1eit70%253D&md5=c458e03fa4a3dc3584a593ac72b3b002</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-03-209262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-03-209262%26sid%3Dliteratum%253Aachs%26aulast%3DVardiman%26aufirst%3DJ.%2BW.%26aulast%3DThiele%26aufirst%3DJ.%26aulast%3DArber%26aufirst%3DD.%2BA.%26aulast%3DBrunning%26aufirst%3DR.%2BD.%26aulast%3DBorowitz%26aufirst%3DM.%2BJ.%26aulast%3DPorwit%26aufirst%3DA.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DLe%2BBeau%26aufirst%3DM.%2BM.%26aulast%3DHellstrom-Lindberg%26aufirst%3DE.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DBloomfield%26aufirst%3DC.%2BD.%26atitle%3DThe%25202008%2520revision%2520of%2520the%2520World%2520Health%2520Organization%2520%2528WHO%2529%2520classification%2520of%2520myeloid%2520neoplasms%2520and%2520acute%2520leukemia%253A%2520rationale%2520and%2520important%2520changes%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26spage%3D937%26epage%3D51%26doi%3D10.1182%2Fblood-2009-03-209262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span> <span> </span><span class="NLM_article-title">The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer</span>. <i>J. Int. Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">656</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1177/147323000803600406</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1177%2F147323000803600406" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=18652760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A280%3ADC%252BD1cvnsVeruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=656-664&author=Q.+Zengauthor=Y.+Chengauthor=Q.+Zhuauthor=Z.+Yuauthor=X.+Wuauthor=K.+Huangauthor=M.+Zhouauthor=S.+Hanauthor=Q.+Zhang&title=The+relationship+between+overexpression+of+glial+cell-derived+neurotrophic+factor+and+its+RET+receptor+with+progression+and+prognosis+of+human+pancreatic+cancer&doi=10.1177%2F147323000803600406"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer</span></div><div class="casAuthors">Zeng Q; Cheng Y; Zhu Q; Yu Z; Wu X; Huang K; Zhou M; Han S; Zhang Q</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of international medical research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">656-64</span>
        ISSN:<span class="NLM_cas:issn">0300-0605</span>.
    </div><div class="casAbstract">We used immunohistochemical staining to assess protein over-expression of glial cell-derived neurotrophic factor (GDNF) and its RET receptor tyrosine kinase in patients with pancreatic cancer and benign pancreatic neoplasm, and assessed correlations with clinicopathological features and prognosis.  Surgically resected pancreatic cancer patients (40/58, 68.9%) showed positive GDNF immunostaining, a significantly higher frequency than in patients with benign pancreatic tumour (3/11, 27.3%).  Intrapancreatic neural invasion by cancer cells was significantly related to over-expression of GDNF.  Strongly positive expression of GDNF was significantly more frequent than lesser grades of expression in patients with severe back pain before and 12 months after surgery.  Expression of RET was significantly related to lymphatic invasion, survival rate after tumour resection and degree of tumour cell differentiation.  We conclude that GDNF may be important in pancreatic cancer proliferation and metastasis, especially in patients with perineural invasion.  Strongly positive expression of GDNF may be an indication for early intensified radiotherapy.  RET expression in pancreatic cancer tissues may be a useful prognostic marker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRb1rJwh9SOLNTiMd2aNQVUfW6udTcc2ebA9EvnjpvYwrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvnsVeruw%253D%253D&md5=41c80625fb4530e36b43aafc7bdd44ac</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1177%2F147323000803600406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F147323000803600406%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DQ.%26atitle%3DThe%2520relationship%2520between%2520overexpression%2520of%2520glial%2520cell-derived%2520neurotrophic%2520factor%2520and%2520its%2520RET%2520receptor%2520with%2520progression%2520and%2520prognosis%2520of%2520human%2520pancreatic%2520cancer%26jtitle%3DJ.%2520Int.%2520Med.%2520Res.%26date%3D2008%26volume%3D36%26spage%3D656%26epage%3D664%26doi%3D10.1177%2F147323000803600406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pancholi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plaza-Menacho, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacke, C. M.</span></span> <span> </span><span class="NLM_article-title">GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">3783</span>– <span class="NLM_lpage">3795</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-4265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1158%2F0008-5472.CAN-12-4265" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=3783-3795&author=A.+Morandiauthor=L.+A.+Martinauthor=Q.+Gaoauthor=S.+Pancholiauthor=A.+Mackayauthor=D.+Robertsonauthor=M.+Zvelebilauthor=M.+Dowsettauthor=I.+Plaza-Menachoauthor=C.+M.+Isacke&title=GDNF-RET+signaling+in+ER-positive+breast+cancers+is+a+key+determinant+of+response+and+resistance+to+aromatase+inhibitors&doi=10.1158%2F0008-5472.CAN-12-4265"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-4265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-4265%26sid%3Dliteratum%253Aachs%26aulast%3DMorandi%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DL.%2BA.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DPancholi%26aufirst%3DS.%26aulast%3DMackay%26aufirst%3DA.%26aulast%3DRobertson%26aufirst%3DD.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DDowsett%26aufirst%3DM.%26aulast%3DPlaza-Menacho%26aufirst%3DI.%26aulast%3DIsacke%26aufirst%3DC.%2BM.%26atitle%3DGDNF-RET%2520signaling%2520in%2520ER-positive%2520breast%2520cancers%2520is%2520a%2520key%2520determinant%2520of%2520response%2520and%2520resistance%2520to%2520aromatase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D3783%26epage%3D3795%26doi%3D10.1158%2F0008-5472.CAN-12-4265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gattei, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldinucci, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Iuliis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzocco, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagonel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, A.</span></span> <span> </span><span class="NLM_article-title">Differential expression of the RET gene in human acute myeloid leukemia</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1007/s002770050444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1007%2Fs002770050444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=9858145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADyaK1cXnsVOhtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=1998&pages=207-210&author=V.+Gatteiauthor=M.+Deganauthor=D.+Aldinucciauthor=A.+De+Iuliisauthor=F.+M.+Rossiauthor=F.+T.+Mazzoccoauthor=M.+Rupoloauthor=V.+Zagonelauthor=A.+Pinto&title=Differential+expression+of+the+RET+gene+in+human+acute+myeloid+leukemia&doi=10.1007%2Fs002770050444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Differential expression of the RET gene in human acute myeloid leukemia</span></div><div class="casAuthors">Gattei, V.; Degan, M.; Aldinucci, D.; Iuliis, A. De; Rossi, F. Maria; Mazzocco, F. Tassan; Rupolo, M.; Zagonel, V.; Pinto, A.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Hematology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">207-210</span>CODEN:
                <span class="NLM_cas:coden">ANHEE8</span>;
        ISSN:<span class="NLM_cas:issn">0939-5555</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">The RET proto-oncogene product is a receptor tyrosine kinase representing the signal-transducing mol. of a multi-subunit membrane receptor complex for at least two different types of transforming growth factor (TGF)-β-related neurotrophic factors.  We have previously shown that RET gene expression in acute myeloid leukemia (AML) occurs more frequently in AMLs displaying either a monocytic (FAB M4/M5) or intermediate-mature myeloid phenotype (FAB M2/M3) than in leukemias reflecting an earlier stage of myeloid differentiation (FAB M0/M1).  To further verify the assocn. between RET expression and the relative maturation stage of AML cells, we have performed a quant. estn. of relative abundances of RET transcripts among various FAB subtypes of AMLs.  By analyzing 13 AML samples and normal hematopoietic cells through a competitive-quant. RT-PCR approach, we were able to show that the relative levels of RET-specific mRNAs continuously increase with blast cell maturation in human AML, i.e., the amts. of RET gene-specific transcripts differ among RET-expressing AMLs, being higher in the more differentiated FAB phenotypes.  In addn., we provide evidence that the relative amts. of RET transcripts increase upon in vitro and in vivo differentiation of leukemic promyelocytes from FAB M3 AML patients, becoming overall comparable to those found in normal granulocytes.  These results indicate that RET expression in human AMLs is maturation-assocd., probably mirroring the developmental regulation of this gene during differentiation of normal hematopoietic cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou4hJ4RRKPWLVg90H21EOLACvtfcHk0lg3DYnAEwjM7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnsVOhtL8%253D&md5=d536906a9dc1d8a3135601e4ecfcd04c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1007%2Fs002770050444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002770050444%26sid%3Dliteratum%253Aachs%26aulast%3DGattei%26aufirst%3DV.%26aulast%3DDegan%26aufirst%3DM.%26aulast%3DAldinucci%26aufirst%3DD.%26aulast%3DDe%2BIuliis%26aufirst%3DA.%26aulast%3DRossi%26aufirst%3DF.%2BM.%26aulast%3DMazzocco%26aufirst%3DF.%2BT.%26aulast%3DRupolo%26aufirst%3DM.%26aulast%3DZagonel%26aufirst%3DV.%26aulast%3DPinto%26aufirst%3DA.%26atitle%3DDifferential%2520expression%2520of%2520the%2520RET%2520gene%2520in%2520human%2520acute%2520myeloid%2520leukemia%26jtitle%3DAnn.%2520Hematol.%26date%3D1998%26volume%3D77%26spage%3D207%26epage%3D210%26doi%3D10.1007%2Fs002770050444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Batalla, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loges, S.</span></span> <span> </span><span class="NLM_article-title">Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?</span>. <i>Expert Rev. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1586/17474086.2015.997704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1586%2F17474086.2015.997704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=25578023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFems7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2015&pages=135-138&author=M.+Janningauthor=I.+Ben-Batallaauthor=S.+Loges&title=Axl+inhibition%3A+a+potential+road+to+a+novel+acute+myeloid+leukemia+therapy%3F&doi=10.1586%2F17474086.2015.997704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?</span></div><div class="casAuthors">Janning, Melanie; Ben-Batalla, Isabel; Loges, Sonja</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Hematology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-138</span>CODEN:
                <span class="NLM_cas:coden">ERHXAV</span>;
        ISSN:<span class="NLM_cas:issn">1747-4094</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Novel treatment options in acute myeloid leukemia (AML) are urgently needed; treatment has not changed significantly over the past decades and survival is still dismal, esp. in elderly patients.  Axl, a member of the Tyro3, Axl, Mer (TAM) receptor family, mediates proliferation and survival of AML cells and is upregulated upon cytostatic treatment.  In addn., AML cells induce expression of the Axl ligand growth arrest-specific gene 6 (Gas6) in bone marrow stroma cells, which further amplifies their growth and therapy resistance.  Interruption of Axl signaling by pharmacol. approaches, including the small mol. Axl inhibitor BGB324, decreased disease burden and prolonged survival of AML mice.  The Gas6-Axl pathway has translational relevance because Axl is expressed by approx. 50% of AML patients and Axl-targeting approaches can block growth of primary human AML cells.  Thus, Axl represents a potential novel target in AML and BGB324 is now in clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkMKGtwTcHcrVg90H21EOLACvtfcHk0lg3DYnAEwjM7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFems7Y%253D&md5=493a441cabca1f0f5aca7614f1283786</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1586%2F17474086.2015.997704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F17474086.2015.997704%26sid%3Dliteratum%253Aachs%26aulast%3DJanning%26aufirst%3DM.%26aulast%3DBen-Batalla%26aufirst%3DI.%26aulast%3DLoges%26aufirst%3DS.%26atitle%3DAxl%2520inhibition%253A%2520a%2520potential%2520road%2520to%2520a%2520novel%2520acute%2520myeloid%2520leukemia%2520therapy%253F%26jtitle%3DExpert%2520Rev.%2520Hematol.%26date%3D2015%26volume%3D8%26spage%3D135%26epage%3D138%26doi%3D10.1586%2F17474086.2015.997704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span> </span><span class="NLM_article-title">NCT02488408</span>.  <i>ClinicalTrials.gov</i>; <span class="NLM_publisher-name">U.S. National Institutes of Health</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, <span class="NLM_year">2015</span>; <a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a> (accessed
Oct 19, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NCT02488408.+ClinicalTrials.gov%3B+U.S.+National+Institutes+of+Health%3A+Bethesda%2C+MD%2C+2015%3B+www.clinicaltrials.gov+%28accessed%0AOct+19%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DNCT02488408%26jtitle%3DClinicalTrials.gov%26pub%3DU.S.%2520National%2520Institutes%2520of%2520Health%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cetkovic-Cvrlje, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uckun, F. M.</span></span> <span> </span><span class="NLM_article-title">Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases</span>. <i>Arch. Immunol. Ther. Exp.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">82</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=15179321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslGqurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2004&pages=69-82&author=M.+Cetkovic-Cvrljeauthor=F.+M.+Uckun&title=Targeting+Janus+kinase+3+in+the+treatment+of+leukemia+and+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases</span></div><div class="casAuthors">Cetkovic-Cvrlje, Marina; Uckun, Fatih M.</div><div class="citationInfo"><span class="NLM_cas:title">Archivum Immunologiae et Therapiae Experimentalis</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">69-82</span>CODEN:
                <span class="NLM_cas:coden">AITEAT</span>;
        ISSN:<span class="NLM_cas:issn">0004-069X</span>.
    
            (<span class="NLM_cas:orgname">Ossolineum Publishing House</span>)
        </div><div class="casAbstract">A review.  Janus tyrosine kinases (JAKs) are cytoplasmic protein tyrosine kinases that play a crucial role in the initial steps of cytokine signaling.  JAK3, a member of JAK kinase family of four (JAK1, JAK2, JAK3 and TYK2), is abundantly expressed in lymphoid cells.  JAK3 has been found to initiate signaling of interleukin (IL)-2, IL-4, IL-7, IL-9, IL-13 and IL-15.  Indispensable role of JAK3 in lymphocyte development and function has been revealed recently.  Because of the involvement of JAK3 in T cell activation and proliferation, and the documented genetic evidence for the role of JAK3 in autoimmune or transplant-induced inflammatory disorders, the selective targeting of JAK3 in T cells may potentially be clin. beneficial in T cell-derived pathol. disorders.  In this review we discuss inhibitors of JAK3 as a new class of immunomodulatory agents with immunosuppressive, anti-inflammatory, anti-allergic, and anti-leukemic properties.  Preclin. data from multiple exptl. model systems of autoimmune diabetes, allergy, solid organ transplantation, pancreatic islet transplantation and bone marrow transplantation are discussed in the context of the clin. need for new immunomodulatory agents with such properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1mQfft89qdrVg90H21EOLACvtfcHk0lg3DYnAEwjM7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslGqurY%253D&md5=0cde7ccfd4752712d48f7ee587ee7975</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCetkovic-Cvrlje%26aufirst%3DM.%26aulast%3DUckun%26aufirst%3DF.%2BM.%26atitle%3DTargeting%2520Janus%2520kinase%25203%2520in%2520the%2520treatment%2520of%2520leukemia%2520and%2520inflammatory%2520diseases%26jtitle%3DArch.%2520Immunol.%2520Ther.%2520Exp.%26date%3D2004%26volume%3D52%26spage%3D69%26epage%3D82" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polzer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krupka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothenberg-Thurley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzeler, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dörfel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salih, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nößner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeremias, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiddemann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subklewe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greif, P. A.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;key=10.1038%2Fleu.2017.257" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=313-322&author=K.+Reiterauthor=H.+Polzerauthor=C.+Krupkaauthor=A.+Maiserauthor=B.+Vickauthor=M.+Rothenberg-Thurleyauthor=K.+H.+Metzelerauthor=D.+D%C3%B6rfelauthor=H.+R.+Salihauthor=G.+Jungauthor=E.+N%C3%B6%C3%9Fnerauthor=I.+Jeremiasauthor=W.+Hiddemannauthor=H.+Leonhardtauthor=K.+Spiekermannauthor=M.+Subkleweauthor=P.+A.+Greif&title=Tyrosine+kinase+inhibition+increases+the+cell+surface+localization+of+FLT3-ITD+and+enhances+FLT3-directed+immunotherapy+of+acute+myeloid+leukemia&doi=10.1038%2Fleu.2017.257"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.257%26sid%3Dliteratum%253Aachs%26aulast%3DReiter%26aufirst%3DK.%26aulast%3DPolzer%26aufirst%3DH.%26aulast%3DKrupka%26aufirst%3DC.%26aulast%3DMaiser%26aufirst%3DA.%26aulast%3DVick%26aufirst%3DB.%26aulast%3DRothenberg-Thurley%26aufirst%3DM.%26aulast%3DMetzeler%26aufirst%3DK.%2BH.%26aulast%3DD%25C3%25B6rfel%26aufirst%3DD.%26aulast%3DSalih%26aufirst%3DH.%2BR.%26aulast%3DJung%26aufirst%3DG.%26aulast%3DN%25C3%25B6%25C3%259Fner%26aufirst%3DE.%26aulast%3DJeremias%26aufirst%3DI.%26aulast%3DHiddemann%26aufirst%3DW.%26aulast%3DLeonhardt%26aufirst%3DH.%26aulast%3DSpiekermann%26aufirst%3DK.%26aulast%3DSubklewe%26aufirst%3DM.%26aulast%3DGreif%26aufirst%3DP.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibition%2520increases%2520the%2520cell%2520surface%2520localization%2520of%2520FLT3-ITD%2520and%2520enhances%2520FLT3-directed%2520immunotherapy%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D313%26epage%3D322%26doi%3D10.1038%2Fleu.2017.257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2G15" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2G15','PDB','2G15'); return false;">PDB: 2G15</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i18"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01605">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_18110"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01605">10.1021/acs.jmedchem.7b01605</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Characterization of compounds, docking studies, and biological methods (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01605/suppl_file/jm7b01605_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01605/suppl_file/jm7b01605_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01605/suppl_file/jm7b01605_si_001.pdf">jm7b01605_si_001.pdf (1.21 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01605/suppl_file/jm7b01605_si_002.csv">jm7b01605_si_002.csv (2.84 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01605&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-5%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01605%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01605" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994f04b95424c7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
